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ABSTRACT 
Carbon monoxide (CO) is an endogenously produced gasotransmitter in mammals and may 
have signaling roles in bacteria as well. It has many recognized therapeutic effects. A significant 
challenge in this field is the development of pharmaceutically acceptable forms of CO delivery 
with controllable and tunable release rates. Our lab has designed a series of organic CO prodrugs 
as prototypes of “carbon monoxide in a pill.” In the first project, a series of such CO prodrugs was 
synthesized to examine the structure-release rate in aqueous solution at neutral pH. 
CO prodrugs with triggered release mechanisms are highly desirable for targeted delivery. In 
the second project, we focused on the development of reactive oxygen species ROS-sensitive CO 
prodrugs, which selectively deliver CO to cells with elevated ROS levels and sensitize cancer cells 
to chemotherapy. CO prodrugs as such could serve as powerful tools for targeted delivery to 
disease sites with elevated ROS levels and for exploring the therapeutic applications of CO. 
In the third project, we focused on metal-free CO prodrugs with dual-responsive endogenous 
triggers, which have the advantage of controlled activation at the desired site of action. These CO 
prodrugs afford highly selective release profiles as compared to others with no or a single trigger. 
In addition, one representative CO prodrug showed significant anti-inflammatory effects both in 
vitro and in an LPS-simulated systemic inflammation models, suggesting its possible application 
in treating systemic inflammatory conditions. The prodrug also conferred very pronounced 
protective effects against LPS-induced acute liver injury. These results firmly established such CO 
prodrugs as either research tools or candidate compounds for the treatment of systemic 
inflammation or other inflammation-related organ injuries.  
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1 ORGANIC CO-PRODRUGS: STRUCTURE CO-RELEASE RATE 
RELATIONSHIP STUDIES  
 
1.1 Introduction 
Carbon monoxide (CO) has long been recognized as a toxic gas and regarded as a “silent 
killer” mainly due to its high affinity for hemoglobin and the fact that many people die from CO 
poisoning every year. Beyond this perception is the fact that CO is also generated endogenously 
in mammals at a rate of about 500 μmol day−1 through the degradation of heme by heme oxygenase 
(Figure 1.1).1, 2 Further, the safe use of therapeutic doses of CO has also been well demonstrated.3 
Now, CO is recognized as an important gasotransmitter with importance on par with that of 
hydrogen sulfide (H2S) and nitric oxide (NO).
4 Moreover, past decades have witnessed the 
demonstration of a myriad of therapeutic indications for CO, including cytoprotection,5 anti-
inflammation,6 antibacteria7-9 and anticancer,10 among many others. However, work in taking CO 
into clinical applications is still in its infancy mainly because of the difficulty in CO delivery in 
pharmaceutically acceptable forms.  
  
 
Figure 1.1. Heme degradation releases bioactive products including CO. 
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1.1.1 Inhalation 
Inhalation of CO gas has been the most widely used CO-delivery form in the past decades 
in animal model studies and in human clinical trials. For example, in 1999, Otterbein and co-
workers reported that CO could provide protection against oxidation stress.11 In this study, it was 
found that CO could significantly attenuate hypoxia-induced lung injury in rats and improve the 
survival rate. Rats exposed to 250 parts/million (ppm) or 500 ppm had a survival rate of 100% 
after 72 h while in contrast rats exposed to hypoxia alone all died.  CO has been well recognized 
as an anti-inflammatory agent by inhibiting expression of the pro-inflammatory cytokine TNF-α 
and augmenting expression of anti-inflammatory cytokine IL-10. In 2004, CO was reported to 
show strong anti-inflammatory effects in a lipopolysaccharide (LPS)-induced multiorgan failure 
rat model at a dose of 250 ppm for 1 h.12  Also, CO was reported to be able to selectively sensitize 
cancer cells to anticancer drugs (e.g., doxorubicin) by 1000-fold due to its anti-Warburg effect, 
which would lead to metabolic exhaustion of cancer cells.13 Another utility of CO’s cytoprotective 
effect is in its attenuation of doxorubicin’s cardiotoxicity. Specifically, CO inhalation was found 
to promote and restore mitochondria biogenesis, and avert the myocardial pathology of Dox.14 
Besides, in 2007 Mota and co-workers reported that exposure to CO gas (250 ppm, at a flow rate 
of ∼12 liter/min, starting on day 3 after infection and continuing for 72 h) was able to greatly 
reduce experimental cerebral malaria (ECM) incidence in C57BL/6 mice. 15  In this study, 
accumulation of free heme in the infected mice was demonstrated as a key component in the 
pathogenesis of ECM and CO was found to be able to suppress the accumulation and oxidation of 
hemoglobin. 
As inhaled CO has shown these promising therapeutic effects in preclinical animal studies, 
several clinical trials had been initiated to test its safety and therapeutic efficacy in humans. For 
3 
example, a very recent Phase II clinical trial in 2019 was set up by Brigham and Women's Hospital 
to test the role of CO in the treatment of acute respiratory distress syndrome (Clinicaltrials.gov 
identifier: NCT03799874). 
Though inhaled CO has been widely applied in animal or clinical studies, it is not an ideal 
delivery form for wide-spread applications due to difficulties in safe administration and in 
controlling doses, lack of portability, and the dependence on individual patient’s respiratory 
function to deliver precise amounts.  Safety issues in case of device malfunction are not trivial 
either. Therefore, a number of labs have been working on developing alternative delivery forms of 
CO for administration through oral or parenteral routes. 
1.1.2 Metal-based carbon monoxide releasing molecules (CO-RMs) 
Much of the earlier work was focused on building molecules with CO immobilized on 
transition metals. These earlier compounds were called CO-releasing molecules, or CO-RMs. 
Since CO is chemically inert and it mainly coordinates with transition metals, most of the CO-
RMs reported so far are transition metal based (Table 1.1).16 For example, the reactivity of CO 
toward metal was demonstrated by its strong interaction with reduced iron in hemoglobin to form 
an iron carbonyl. In 2002, Motterlini and co-workers reported a series of transition-metal based 
CO-RMs: dimanganese decacarbonyl (CO-RM-1) and tricarbonyldichlororuthenium (II) dimer 
(CO-RM-2), both of which release CO in a concentration–dependent manner.17 CO-RM-1 was 
shown to release CO only when it exposed to light while CO-RM-2 was shown to release CO 
spontaneously in DMSO. In 2003, Motterlini and co-workers also reported a new water-soluble 
CO-RM, tricarbonylchloro(glycinato)ruthenium(II) (CO-RM-3), which readily releases CO in 
buffer under near physiological conditions.18 It was found that CO-RM-3 (10 μmol/L) attenuated 
cell injury in a concentration-dependent manner at reoxygenation. Specially, H9c2 cells showed 
4 
approximately 70% loss in cell viability when exposed to hypoxia for 24 hours and reoxygenated 
for 6 hours while cells treated with 25 μmol/L didn’t show any loss in cell viability.  
In 2004, Green and Motterlini developed a transition-metal free CORM, Na2[H3BCO2] 
(CO-RM-A1) (CO-RM-A1), which has a slower half-life (~21 min at 37 °C and pH 7.4) than 
previous CO-RMs and thus offer the advantage of sustained duration of CO exposure.19 Further, 
administration of CO-RM-A1 led to a similar vasorelaxation effect in isolated aortic rings as the 
metal-based CO-RMs. Though CO-RM-A1 does not have transition metal, it does lead to the 
release of one equivalent of BH3, the health effect of which needs to be further examined.  
Subsequently, other labs also reported many metal-based CO-RMs, which are able to 
release CO either spontaneously or upon light irradiation.20-22 For example, Mascharak and co-
workers reported a number of photo-sensitive CO-RMs23 including  
[Mn(CO)3(phen)(PTA)]CF3SO3, which was shown to release CO upon exposure to visible light.
24 
Interestingly, CO delivered by this CO-RM was found to sensitize cancer cells to doxorubicin by 
disrupting the redox homeostasis in breast cancer cells (MCF-7, MDA-MB-468, and Hs 578T). It 
was found that CO was able to inhibit cystathionine β-synthase (CBS) and further attenuate the 
ratio of reduced to oxidized glutathione (GSG/GSSG) which is frequently used as an indication of 
intracellular antioxidant capacity and redox homeostasis.  A subsequent study in 2019 also showed 
sensitization effect on cisplatin-resistant ovarian cancer cells toward cisplatin via the same 
mechanism.25  
Table 1.1Reported metal-containing CO-RMs Structures and CO-Release properties 
Compounds Chemical structure Half-life (t1/2) 
Mn2[CO]10(CO-RM-1) 
 
< 1 min 
5 
 
1.1.3 Esterase and protease sensitive CO-RMs 
All metal-based CO-RMs discussed above have clearly demonstrated the feasibility of 
using CO-RMs as CO donors as research tools and for potential pharmacological applications. 
However, for many metal-based CO-RMs, CO release was relying on the reactions with water, pH 
changes or the presence of oxygen. Thus, it is very hard to control the amount of CO to be released 
or to delivery CO to the desired site. One way to overcome such limitations is to use stable 
 (Ru[CO]3Cl2)2(CO-RM-2) 
 
≈ 1 min 
Ru[CO]3Cl-glycinate(CO-RM-3) 
 
≈1 min (37°C, pH = 7.4) 
Na2[H3BCO2] (CO-RM-A1) 
 
≈ 21 min (37°C, pH = 7.4) 
Mn[CO]4[S2CR] (CORM-S1) 
 
< 4 min 
[Mn(CO)3(tpm)]PF6 
 
NA 
[FeII(CO)(N4Py)]
2+ 
 
>1 day in aerobic water or 
phosphate buffer 
[Mn(CO)3(phen)(PTA)]CF3SO3 
 
≈1.3 min 
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molecules as precursors, which could be triggered to release CO.  Enzyme triggered CO-RMs (ET-
CO-RMs) seems to be a good option to meet this need. In 2011, Schmalz and co-workers proposed 
acyloxybutadiene-iron tricarbonyl complexes as esterase-activated ET-CO-RMs (Figure 1.2).26 
The rationale behind this design is that stable dienyl ester complexes could be cleaved by 
intracellular esterase and the ensuing enolization would lead to iron dissociation and oxidation to 
Fe3+ and subsequent CO release. In this study, the CO release triggered by esterase was confirmed 
by a myoglobin (Mb) assay. The author confirmed that ET-CO-RMs could present potent anti-
inflammatory effect by inhibition of NO production in LPS-stimulated RAW267.4 cells. In 2012, 
the same group reported a series of (phosphoryloxy diene)Fe(CO)3 complexes as water-soluble 
ET-CO-RMs for future application.27 
 
Figure 1.2 Mechanism of esterase-activated ET-CO-RMs 
 
Beside esterase-activated ET-CO-RMs, Dr. Schmalz’s group has also designed a series of 
protease-activated ET-CO-RMs by connecting an oxydiene–Fe(CO)3 complexes with a Penicillin 
G Amidase (PGA) cleavable side chain in 2015 (Figure 1.3).28 It was demonstrated that after 
cleavage of the amide bond by amidase, the following residue would undergo decay and release 
of CO which is similar to the case in esterase-activated CO-RMs. 
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Figure 1.3Mechanism of protease-activated ET-CO-RMs 
 
ET-CO-RMs are clever designs for controlled release of CO. However, such design was 
mainly relying on the modification of metal-based CO-RMs. Undoubtedly, metal-based CO-RMs 
have made substantial contributions to the understanding of CO’s biological effects. However, 
their clinical applications as therapeutic agents are somewhat hampered due to possible or may 
even just perceived metal toxicity issues. Consequently, encapsulated CO-RMs and photosensitive 
organic CO-RMs have been developed, aimed at addressing metal toxicity and targeted delivery 
issues. 
 
1.1.4 CO delivery in encapsulated form 
To achieve better targeting efficiency and reduce potential metal toxicity, many groups 
have worked on encapsulating CO-RMs in micelles, nanoparticles, and other capsules.28-31 For 
example, in 2010 Hubbell and co-workers reported a CO delivery system using micelles.29 
Basically, the micelles contain three blocks: a hydrophilic poly(ethylene glycol) block, a 
poly(Ru(CO)3Cl (ornithinate acrylamide) block capable of releasing CO, and a hydrophobic 
poly(n-butylacrylamide) block. These micelles were found to be stable under physiological 
conditions in buffer or serum, and release CO in response to thiol species such as cysteine.   
In addition to CO-RM containing micelles, other new encapsulated forms of CO donors 
have also been developed. For example, in 2016 Maruyama and co-workers reported a type of CO 
8 
donor named CO-bound HbV (CO-HbV), in which the highly concentrated COHb solution was 
encapsulated inside a phospholipid bilayer membrane (liposome).32 Also, this CO-HbV was 
reported to possess strong anti-inflammatory and antioxidative effects in the progression of 
idiopathic pulmonary fibrosis and inflammatory bowel disease.  
The encapsulated of CO delivery is a clever design in terms of addressing metal toxicity. 
However, the metabolism of remaining encapsulating materials is still a concern for the application 
of such a strategy. 
1.1.5 Photosensitive organic CO-RMs 
To avoid any metal-related toxicity issues as discussed above, organic forms of CO-RMs 
were sought by many groups. In 2013, Klán and co-workers reported a water-soluble fluorescein 
analogue as the first metal-free photo-sensitive CO-RM which releases CO when exposed to 
visible light (Figure 1.4).33  The half-life of decomposition of this fluorescein analogue in 
phosphate buffer saline buffer (PBS) was determined to be around 4.5 h when irradiated at 500 
nm. However, this fluorescein analog is hard to synthesize, and thus the chromophore was 
modified leading to a series of boron-dipyrromethenes (BODIPY) as photosensitive CO-RMs in 
2016.These CO-RMS respond to visible-to-near IR(NIR) light (up to 730 nm), leading to 
activation and CO release.34 The longer wavelength of absorption would allow better penetration 
of the light in the tissue and thus enhance their compatibility with biological applications. 
 
Figure 1.4 The photo-release mechanism for fluorescein analogue 
 
  
9 
Other researchers including Dr. Berreau’s and Dr. Popik’s group have also made extensive 
efforts in this area.35, 36 Undoubtedly, organic photosensitive CO-RMs with spatiotemporal control 
and minimized offsite effects have made substantial contributions to the development of organic 
CO prodrugs. However, there are more efforts needed to solve remaining concerns. For example, 
the penetration of light into deep tissue needs to be improved and structure modifications toward 
tunable release rates are also needed for future application. 
 
Table 1.2 Reported photo-sensitive organic CO-RMs structures and CO-release 
properties 
 
1.1.6 Organic CO prodrugs 
 We strongly believe the potential of using CO for treatment of human diseases. However 
as with any drug discovery and development program, developability issues occupy a special place 
in determining the likelihood of success.37-39 As a result, we are interested in compounds that do 
more than releasing CO. Instead, we are very interested in the pharmaceutical developability of 
CO-RMs Wavelength (nm) Release rate 
 
500 t1/2 = 270 min 
 
470 Finish in 10 min 
 
419 Finish in 8 min 
 
419 or   > 546 Finish in 10 min 
 
300 
              
Finish in 5 min 
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such CO donors and their properties in the context of drug developability. For all these, we believe 
the need to take the CO donor work one step further in designing CO prodrugs, which take into 
consideration of developability issues as defining distinctions from CO-RMs. Therefore, the Wang 
lab is interested in the development of organic CO-prodrugs, which do not require light activation, 
can release CO under physiological conditions with tunable release rates, and are amenable to 
structural optimizations with regard to ADMET properties.  
Ideal CO-prodrugs should have following desired properties: (1) CO release under 
physiological conditions; (2) devoid of any reactive functional groups or toxic ingredient; (3) 
amenable to optimization to tune the release rate; (4) triggered release of CO; and (5) suitable 
pharmaceutical properties for eventual human application.  
In 2014, our lab reported the very first “click and release” CO prodrug system.40 
Specificaly, the initial design takes advantage of a bimolecular inverse-electron-demand Diels 
Alder reaction (DAinv) between a strained alkyne (bicyclo-[6.1.0]nonyne (BCN) and 
tetraphenylcyclopentadienone (TPCPD) to form a very strained intermediate, which undergoes a 
spontaneous chelatropic reaction to release CO under physiological conditions. The second order 
rate constant of such reactions was determined to be 0.61 M-1S-1 in aqueous solution or methanol 
at room temperature. Co-treatment of Raw 264.7 cells with both two compounds (1 mM) led to a 
50% decrease of the LPS-induced production of TNF-α, while treatment of either compound alone 
had no such effect. Thus, this experiment successfully demonstrated the anti-inflammatory effect 
of CO and the chemical feasibility of using Diels-Alder reactions to design “click and release” CO 
prodrug systems. 
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Figure 1.5 A bimolecular click and release prodrug system  
 
To achieve better targeting efficiency and reduce potential metal toxicity, many groups 
have worked on encapsulating CO-RMs in micelles, nanoparticles, and other capsules.28-31 For 
example, in 2010 Hubbell and co-workers reported a CO delivery system using micelles.29 
Basically, the micelles contain three blocks: a hydrophilic poly(ethylene glycol) block, a 
poly(Ru(CO)3Cl (ornithinate acrylamide) block capable of releasing CO, and a hydrophobic 
poly(n-butylacrylamide) block. These micelles were found to be stable under physiological 
conditions in buffer or serum, and release CO in response to thiol species such as cysteine.   
In addition to CO-RM containing micelles, other new encapsulated forms of CO donors 
have also been developed. For example, in 2016 Maruyama and co-workers reported a type of CO 
donor named CO-bound HbV (CO-HbV), in which the highly concentrated COHb solution was 
encapsulated inside a phospholipid bilayer membrane (liposome).32 Also, this CO-HbV was 
reported to possess strong anti-inflammatory and antioxidative effects in the progression of 
idiopathic pulmonary fibrosis and inflammatory bowel disease.  
The encapsulated of CO delivery is a clever design in terms of addressing metal toxicity. 
However, the metabolism of remaining encapsulating materials is still a concern for the application 
of such a strategy. 
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Figure 1.6 A unimolecular click and release prodrug system 
 
1.2 Results and discussion 
1.2.1 Design of CO prodrugs 
Among the various features that we are interested in working on, we view the tunability of 
release rates being a critical one. Because of the volatile nature of CO, the release half-life plays a 
determining role in the effective CO concentration and duration of action. Moreover, we believe 
that CO prodrugs with different releasing profiles are required for different applications. Herein, 
we describe the first comprehensive study of the relationship between structure and CO release 
rate for three classes of CO prodrugs. Among them, scaffold I was reported in our previous 
unimolecular prodrug work as shown in Figure 1.6.41 Meanwhile, two other new structural 
scaffolds (Figure 1.7, Scaffolds II and III) for the same purpose are also introduced here.42 
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Figure 1.7 General structures of CO prodrugs and their CO release mechanism 
 
The general design of this class of CO prodrugs cages a CO molecule in the form of a 
ketone carbonyl group in a substituted cyclopentadienone and relies on a Diels-Alder reaction with 
an alkyne for the release of CO under physiological conditions.  In designing new analogs, we 
separate these CO prodrugs into three types. Type I represent an extension of our earlier work on 
fusing a cyclopentadienone ring with a naphthalene ring, which forms a fluorescent product after 
CO release, and thus allow for the real-time monitoring of CO formation.41 In this scaffold, the 
alkyne group is tethered to the cyclopentadienone moiety through a linear linker containing either 
an ester or amide functional group. The structural modifications to scaffold I were primarily made 
to the substituent on the cyclopentadienone ring (R4, Figure 1.7), the nature of the tethering linker 
(X, Figure 1.7), and the substituents on the tethering linker (R1-R3, Figure 1.7). In type II, the linker 
has a phenyl ring structure, providing additional conformational constraints. In addition, a carboxyl 
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group in scaffold II can be used for structural optimization or for tethering additional structures 
for targeting and other applications. Similar structural modifications were also made to Scaffold II 
(X, Y and R1) to probe the structure-release rate relationship. CO prodrugs with Scaffolds I and II 
both possess a naphthalene group fused with the dienone ring. However, the introduction of 
naphthalene ring is also accompanied with decreased water solubility due to its rigid and flat 
structural nature. Moreover, the fluorescent reporter is not necessarily needed for eventual clinical 
applications. Therefore, CO prodrugs with Scaffold III were also designed. In this class, each of 
the 3, 4 positions of the cyclopentadienone moiety is substituted with an individual aryl ring. This 
affords additional structural diversity and flexibility. Further modifications followed a similar 
approach as for Scaffolds I and II. 
In considering the design, one critical factor is the balance of the reactivity needed for 
cycloaddition in aqueous solution at neutral pH, and stability in organic solvent and during storage. 
It has been reported that water and protein binding accelerate Diels-Alder reactions by thousands 
of folds, largely driven by hydrophobic forces.43-47  This allows the possibility for CO-prodrugs to 
be prepared in organic solvents, remain stable during storage, and yet readily undergo 
cycloaddition in an aqueous solution to release CO. 
1.2.2 Synthesis of CO prodrugs 
CO prodrugs BW-CO-104-106, 108-113 with different tethering linkers and substituents 
were synthesized according to our previous procedures.41 Briefly, compound 1a-b were condensed 
with a variety of alcohol or amine to afford compounds 2a-i, which were found to exist as a mixture 
of keto-enol tautomers (Scheme 1). Compounds 2a-i were then reacted with acenaphthylene-1,2-
dione, followed by treatment with an acid for dehydration to yield the desired CO prodrugs BW-
CO-104-106, and 108-113 in 20-77% yield. CO prodrug BW-CO-114 with a (2,5,8,11,14,17-
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hexaoxanonadecan-19-yl)oxyl group was also synthesized in order to improve water solubility and 
biocompatibility (Scheme 1.2). Briefly, compound 4 was synthesized by alkylation of compound 
3, and was subsequently hydrolyzed to afford compound 5 in 98% yield. Compound 5 was then 
condensed with 2, 2-dimethyl-1,3-dioxane-4,6-dione using EDC as the coupling regent to afford 
compound 6. BW-CO-114 was then obtained by a similar dehydration method used for the 
synthesis of BW-CO-104-106, 108 – 113 as shown in Scheme 1.1. 
 
Scheme 1.1 Synthesis of CO prodrugs BW-CO-104-106, 108 – 113 with scaffold I.  
Reagents and conditions: i) toluene, substituted alcohol or amine, reflux, 1-2 h; ii) 1) 
acenaphthylene-1,2-dione, Et3N, MeOH/THF (1:2), r.t, 1-3 h, 2). H2SO4, Ac2O, 0 °C to r.t, 1- 2 h  
 
 
Scheme 1.2 Scheme 2. Synthesis of CO prodrugs BW-CO-114 with scaffold I.  
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Reagents and conditions: i) 2,5,8,11,14,17-hexaoxanonadecan-19-yl 4-methylbenzenesulfonate, 
NaH, THF, 0 oC - r.t, 24 h; ii) LiOH, MeOH/H2O, r.t, 24h; iii) 2,2-dimethyl-1,3-dioxane-4,6-
dione, Et3N, MeOH/THF (1:2), r.t, 1-3 h, 2). H2SO4, Ac2O, 0 °C to r.t, 1- 2 h 
 
Next, we synthesized CO prodrugs with Scaffold II. As shown in Scheme 1.3, compound 8 was 
alkylated under basic condition to afford compounds 9a/b. CO prodrugs BW-CO-115-116 were 
then readily synthesized by a series of reactions similar to those used for the synthesis of BW-CO-
114 (Scheme 1.2). Meanwhile, in order to probe the effects of substituent on the linker for the CO 
release rate, CO prodrugs BW-CO-117/118 were also synthesized as shown in Scheme 1.4. 
Initially, we tried to employ methyl 2-(2-aminophenyl)acetate as the starting material to make 
BW-CO-117/118, by following similar approaches used for BW-CO-115/116.However, unlike 
its phenol counterpart (8), methyl 2-(2-aminophenyl)acetate is unstable, and is prone to 
intramolecular lactamization to form a five-membered lactam ring. Consequently, compound 13 
was used as the starting material, which was sulfonated and alkylated to afford compounds 15a/b. 
The deprotection of the TBS group and subsequent oxidation of the alcohol to acid 16a/b was 
accomplished in one pot by using KF and Jones reagent in acetone at room temperature. With 
compounds 16a/b in hand, the synthesis of BW-CO-117 /118 was straightforward by a series of 
similar reactions used for BW-CO-114.  However, in the case of BW-CO-118, BW-CP-118 was 
afforded as the major product at the dehydration step, presumably due to the fast cycloaddition of 
BW-CO-118 under such conditions. The synthesis of CO-prodrugs of Type III is depicted in 
Scheme 1.5. Intermediate 2a, 2e and 2f described in Scheme 1.1 were further reacted with benzil 
in the presence of KOH to yield the aldol intermediates, which were used directly for the 
dehydration step without purifications to afford BW-CO-119 - 121 as red solid. 
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Scheme 1.3 Synthesis route of BW-CO-115 - 116 with scaffold II.  
Reagents and conditions: (i) propargyl bromide or 3-butyn-2-yl 4-methylbenzenesulfonate, 
K2CO3, ACN, reflux, 4 h; (ii) KOH, H2O/methanol (1:1), r.t, 1 h; (iii) 2,2-dimethyl-1,3-dioxane-
4,6-dione, DMAP, EDC, DCM, r.t, 12 h; (iv) morpholine, trimethylsilyl chloride (TMSCl), 
chlorobenzene, reflux, 3 h; (v) acenaphthylene-1,2-dione, Et3N, MeOH/THF (1:2), rt, 3 h, then 
H2SO4, Ac2O, 0 °C to r.t, 1 h. 
 
 
Scheme 1.4 Synthesis route of BW-CO-117 - 118 with scaffold II.  
Reagents and conditions: (i) MsCl, pyridine, DCM, 0°C to r.t, 20 h; (ii) propargyl bromide or 3-
butyn-2-yl 4-methylbenzenesulfonate, K2CO3, ACN, reflux, 4 h; (iii) KF, Jones reagent, acetone, 
rt, 20 h; (iv) 2,2-dimethyl-1,3-dioxane-4,6-dione, DMAP, EDC, DCM, rt, 12 h; (v) morpholine, 
TMSCl, chlorobenzene, reflux, 3 h; (vi) 1). acenaphthylene-1,2-dione, Et3N, MeOH/THF (1:2), 
r.t, 3 h; 2). H2SO4, Ac2O, 0 °C to rt, 1 h. 
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Scheme 1.5 Synthesis of the CO prodrugs BW-CO-119 - 121 with scaffold III.  
Reagents and conditions: i) 1).benzil, KOH, rt, 15 h; 2). H2SO4, Ac2O, 0 °C to r.t, 15 min.  
 
 
1.2.3 CO release kinetics and structure CO release rate relationships 
With all the CO prodrugs in hand, we next studied their CO release rates in a mixed aqueous 
solution (DMSO/PBS = 4/1, 37 oC). For CO prodrugs of Scaffolds I and II, their CO release 
kinetics were easily determined by monitoring the increase of the fluorescent intensity at different 
time points. For CO prodrugs of Scaffold III, since the CO prodrugs have a UV absorbance peak 
at around 360 nm, and yet the cyclized product has no absorbance at this wavelength, the CO 
release rate was indirectly determined by monitoring the decrease of UV absorbance at 360 nm. 
The CO release kinetics for the CO prodrugs are summarized in Tables 1.2, 1.3 and 1.4. 
As shown in Table 1.3, all the CO prodrugs of Type I can readily undergo intramolecular 
cycloaddition to release CO. The CO release was confirmed by the structural elucidation of the 
fluorescent cycloaddition products BW-CP-104 - 106, 108 – 114, a commercial CO detector and 
a CO myoglobin assay. Three major factors are important in influencing the reaction rates: (1) the 
nature of the X, which determines whether it is an ester or amide, (2) additional substituents on 
the linear linker, which may impose additional conformational constraints favoring the 
cycloaddition reaction and thus CO release rates, and (3) the linker length, which determines 
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whether cycloaddition would lead to a five- or six-membered ring formation. Generally, CO-
prodrugs with an amide linker lead to faster CO release as compared to those with an ester linker.  
For example, the half-lives of BW-CO-108/109 (t1/2 = 55.6 or 0.55 h) with an ester linker were 
much longer than BW-CO-110/111(t1/2 = 12 or 0.2 h) with an amide linker. This is understandable 
because amide bond is not as freely rotatable as an ester bond, and thus provides an entropic 
advantage in such cycloaddition reactions. It is well known that “gem-dialkyl” effect can greatly 
accelerate ring-closure reaction.48 Indeed, we find that the introduction of a gem-dimethyl group 
accelerates the cycloaddition rate significantly. For example, the half-lives for BW-CO-109 and 
BW-CO-111 are only around 0.55 and 0.20 h, respectively, which represent a more than 1000-
fold difference as compared to BW-CO-105/106 (t1/2 > 10 days), which do not have this gem-
dimethyl group. By the same token, the introduction of one methyl group on the tethering linker 
also enhances the cycloaddition rate. For example, BW-CO-106 has a half-life of more than 10 
days while BW-CO-110 has a much shorter half-life of 12.0 h after introducing a methyl group.  
An additional observation related to water solubility and CO-release rate is also very 
interesting. The introduction of a PEG linker to the phenyl ring in BW-CO-114 slightly decreases 
the CO release rate (t1/2 = 97 h vs t1/2 =56 h of BW-CO-108). It is possible that the introduction of 
a hydrophilic unit close to the reaction site disfavors a process that is partially driven by 
hydrophobic forces. Unexpectedly, substituting the phenyl (BW-CO-109/111) on the dienone 
moiety with a methylthio group (BW-CO-112/113) does not make much of a difference in terms 
of CO release rate. Compared to a phenyl group, the methylthiol group is, albeit weak, an electron 
donating group, and should increase the LUMO energy level of the dienone compound, resulting 
in a decrease in the cycloaddition rate. Indeed, computational calculations of the partial charge 
distribution show that the electron density of dienone ring with a methythiol group (BW-CO-
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112/113) is higher than that of BW-CO-109/112. However, the results show that there is no 
significant difference in CO release rate between these two types of analogues, indicating that 
entropy factors dominated in rate acceleration instead of electron density on the dienone ring in 
such cases. This also opens a door for introducing substituents of varying electronic properties on 
the phenyl ring for structural diversity. 
Table 1.3 CO release kinetics for CO prodrugs with scaffold I. 
 
 
 
 
Compounds  k (h-1) [a] t1/2 (h) [b] 
BW-CO-104: X = -N-iso-propyl, R1 = H, R2 = H, R3= Me, n = 2 0.11±0.03 6.2±0.2 
BW-CO-105: X = O, R1 = H, R2 = H, R3 = H, R4 = phenyl, n= 1 - > 10 days 
BW-CO-106: X = NH, R1 = H, R2 = H, R3 = H, R4 = phenyl, n= 1 - >10 days 
BW-CO-108: X = O, R1 = Me, R2 = H, R3 = H, R4 = phenyl, n= 1 0.012±0.0003 55.6±1.5 
BW-CO-109: X = O, R1 = Me, R2 = Me, R3 = H, R4 = phenyl, n= 1 1.28±0.18 0.55±0.08 
BW-CO-110: X = NH, R1 = Me, R2 = H, R3 = H, R4 = phenyl, n= 1 0.058±0.003 12.0±0.74 
BW-CO-111: X = NH, R1 = Me, R2 = Me, R3 = H, R4 = phenyl, n= 1 3.31 ±0.28 0.20±0.02 
BW-CO-112: X = NH, R1 = Me, R2 = Me, R3 = H, R4 = methylthio, n= 1 4.63±0.28 0.15±0.009 
BW-CO-113: X = O, R1 = Me, R2 = Me, R3 = H, R4 = methylthio, n= 1 1.29±0.07 0.53±0.04 
BW-CO-114: X = O, R1 = Me, R2 = H, R3 = H, R4 = PEG substituted phenyl 
group, n = 1 
0.0072±0.0003 96.85±4.45 
 [a] CO release rate was determined by monitoring the increase of fluorescence intensity in DMSO/PBS (pH = 7.4) 4:1 at 37 °C. [b]  
Half-life for CO release; 
 
As shown in Table 1.4, all the synthesized CO prodrugs with scaffold II can release CO 
and generate a fluorescent reporter in DMSO/PBS (4:1) at 37 oC as well. The CO release was 
verified by structural elucidation of the cyclized products, a commercial CO detector and a CO 
myoglobin assay. As for the CO release rate, the introduction of a ring structure on the linker did 
not seem to afford general rate enhancement. The CO release rates are in the same general range 
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as that of Type I. Among the three analogs studied in Table 1.4, the N-methanesulfonyl aniline 
linker seems to provide faster CO release rates. For example, BW-CO-117 with an N-
methanesulfonyl group as “X” has a release half-life of 0.78 h. In comparison, compound BW-
CO-115, which has an oxygen as the “X” group has a release half-life of 6.74 h. Such results are 
in agreement with the conformational constraints imposed by the N-methanesulfonyl aniline 
structure as compared to a phenol oxygen in the same place. The introduction of one methyl group 
into the tethering linker also enhanced the CO release. For example, BW-CO-115 has a half-life 
of 6.74 h while BW-CO-116, which has a methyl group on the linker, has a half-life of only 2.25 
h. This is the same trend as observed in the CO prodrugs of scaffold I. 
Table 1.4 CO release kinetics for CO prodrugs with scaffold II. 
 
 
 
 
 
Compounds  k (h-1) [a] t1/2 (h) [b] 
BW-CO-115: X = O, R1 = H, Y = morpholine 0.10±0.003 6.74±0.21 
BW-CO-116: X = O, R1 =Me, Y = morpholine 0.308±0.003 2.25±0.03 
BW-CO-117: X = NMs, R1 = H, Y = morpholine 0.882±0.012 0.78±0.01 
[a] CO release rate was determined by monitoring the increase of fluorescence intensity in DMSO/PBS (pH = 7.4) 4:1 at 37 °C. [b] 
Half-life for CO release; 
 
As shown in Table 1.5, the CO prodrugs with Scaffold III also readily release CO in 
DMSO/PBS (4:1) at 37 oC. Intriguingly, the CO release rates for prodrugs of Scaffold III are much 
faster than that of the corresponding CO prodrugs of Scaffold I. For example, the half-life for BW-
CO-104, 105 and 108 of Scaffold I is more than 6 h, 10 days and 55 h, respectively, and yet the 
half-life for their Scaffold III counterparts is only 1h, 4 min, and 7 min, respectively. Interestingly, 
results from computational studies indicate that conjugation of phenyl ring would lower the 
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electron density of the dienone ring especially at the C4 position. It is possible that the conjugation 
afforded by the phenyl ring in Scaffold III prodrugs increases the reactivity of the 
cyclopentadienone structure in a Diels-Alder reaction by lowering the LUMO energy level of the 
dienone ring. In addition, BW-CO-121 (t1/2 = 0.97 h) with an amide linker is found to release CO 
at a slower rate than BW-CO-119 (t1/2 = 0.12 h), despite the fact that it has an amide group, while 
BW-CO-119 has an ester linker. Such results further indicate that the size of the ring formed from 
the tether plays an important role as well. It is clear that lactam/lactones of five-membered rings 
formed by BW-CO-119 is favored over six-membered ring formed by BW-CO-121, leading to 
enhanced CO release rates. Besides, introduction of one methyl group on the tethering linker 
increases the CO release rate (t1/2 = 0.073 h of BW-CO-120 vs t1/2 = 0.12 h of BW-CO-119), 
which is similar to our previous findings in Scaffold I. 
Table 1.5 CO release kinetics for CO prodrugs with scaffold III. 
 
 
1.2.4 Cytotoxicity study 
The cytotoxicity of BW-CO/CP-104 has been tested in our previous work and these 
compounds showed no cytotoxicity at up to 100 μM.41 Cytotoxicity of the rest CO prodrugs along 
 
 
 
 
 
Compounds  k (h-1) [a] t1/2 (h) [b] 
BW-CO-119: X = O, R1 = H, R2 = H, R3 = H, n = 1 5.89±0.91 0.12±0.02 
BW-CO-120: X = O, R1 = H, R2 = Me, R3 = H, n = 1 9.39±1.07 0.073±0.013 
BW-CO-121: X = -N-iso-propyl, R1 =Me, R2 = H, R3 = H, n = 2 0.72±0.08 0.97±0.11 
[a] CO release rate was determined by monitoring the decrease of absorbance at 360 nm in DMSO/PBS (pH = 7.4) 4:1 at 37 °C. [b] Half-life 
for CO release. 
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with their corresponding products after CO release was studied in Raw 264.7 cells with a drug 
exposure time of 24 h. The results revealed that most of the compounds tested did not present 
obvious cytotoxicity at 100 μM, and only a few CO prodrugs (BW-CO-112, 113, 115, 116, 120, 
121) and inactive products (BW-CP-111/115/120) showed cytotoxicity with IC50 values in the 
range of 50-100 μM. Clearly, there is no general intrinsic toxicity issues related to this class of 
compounds, but idiosyncratic toxicity may occur with individual compounds, which can also be 
addressed by structural optimizations.   
1.2.5 Intracellular CO release 
Having confirmed that all the prodrugs readily undergo intramolecular cycloaddition to 
release CO in a mixed aqueous solution, we next probed whether they would release CO in a 
biological milieu. To this end, prodrugs BW-CO-109 (Scaffold I), 117 (Scaffold II), and 119 
(Scaffold III) were chosen as representatives to study intracellular CO release in Raw 264.7 cells. 
For BW-CO-109/117, the intracellular CO release was monitored by the blue fluorescence of the 
cyclized product. For BW-CO-119, the CO release was verified by using a reported CO 
fluorescent probe COP-1.49  As shown in Figure 1.8, the cells treated with BW-CO-109 and 117 
showed dose-dependent blue fluorescence formation, which indicated CO release intracellularly. 
For BW-CO-119, the cells treated with prodrug and COP-1 showed strong green fluorescence in 
a dose dependent fashion, and the cells treated with COP-1 alone showed only negligible green 
fluorescence. Altogether, these results indicated that all the CO prodrugs would release CO in a 
biological matrix. 
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Figure 1.8 Fluorescence imaging of fixed Raw 264.7 cells 
A: Fluorescence imaging of fixed Raw264.7 cells treated with COP-1. (a: 1 μM) only, or COP-1 
(1 μM) + BW-CO-119 (b: 25 μM, c: 50 μM) under FITC channel. B: Fluorescence imaging of 
fixed Raw264.7 cells treated with BW-CO-109. 
 
1.3 Experimental Section 
1.3.1 General information 
All reagents and solvents were of reagent grade and were purchased from Aldrich. 1H-
NMR (400 MHz) and 13C-NMR (100 MHz) spectra were recorded on a Bruker Avance 400 MHz 
NMR spectrometer.  Mass spectral analyses were performed on an ABI API 3200 (ESI-Triple 
Quadruple). Fluorescence spectra were recorded on a Shimadzu RF-5301PC fluorometer and UV 
absorption spectra were obtained with Shimadu UV-1700. Compound 1a, 2a-c, BW-CO-104 – 
106, 2,5,8,11,14,17-hexaoxanonadecan-19-yl 4-methylbenzenesulfonate and COP-1 were 
synthesized following literature procedures.49, 50 
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1.3.2 Experimental procedure for the synthesis of CO prodrugs 
Synthesis of compound 1b: To a solution of 2-(methylthio)acetic acid (6.0 mmol) in 
anhydrous DCM (3 ml), Meldrum’s acid (0.9 mmol, 1.5 equiv.) and DMAP (9.0 mmol, 1.5 equiv.) 
were added. The solution was cooled to 0 °C and EDC (9.0 mmol, 1.5 equiv.) was added slowly 
under protection of argon. After stirring at 0 °C for 1 h, the reaction mixture was allowed to warm 
to room temperature and then stirring continued for another 6 h. Then the reaction was quenched 
by aqueous HCl solution (1M, 30 mL) and extracted with EtOAc (3 × 25 ml). The combined 
organic phase was dried over anhydrous Na2SO4, evaporated under reduced pressure to afford the 
crude product, which was further purified by silica gel column chromatography to afford the pure 
product as a white solid (83%). 1H NMR (CDCl3) δ 15.28 (s, 1H), 3.94 (s, 2H), 2.26 (s, 3H), 1.75 
(s, 6H). 13C NMR (CDCl3) δ 193.1, 170.7, 160.1, 105.2, 90.4, 35.8, 26.9, 16.6.  
General procedure A for the synthesis of compound 2: To a solution of 1a or 1b (1.5 
mmol) in toluene (4 mL), the corresponding alcohol or amine(2.3 mmol, 1.5 equiv.) were added. 
The solution was heated at reflux for 1-2 h, after which the reaction mixture was concentrated 
under vacuum, and the residue was directly purified by column chromatography to afford the 
desired product. 
2d: colorless oil, yield, 90%. 1H NMR (CDCl3) δ 7.38 – 7.27 (m, 3H), 7.24 (d, J = 6.8 Hz, 
2H), 5.51 – 5.45 (m, 1H), 3.85 (s, 2H), 3.49 (s, 2H), 2.50 (d, J = 2.0 Hz, 1H), 1.53 (d, J = 6.8 Hz, 
3H).  13C NMR (CDCl3) δ 199.9, 165.9, 133.1, 129.6, 128.9, 127.4, 81.4, 73.4, 61.1, 50.0, 48.1, 
21.1. HRMS (ESI)+ calculated for C14H14O3 [M+Na]
+ m/z 253.0835, found 253.0836. 
2e: Colorless oil, yield, 70% 1H NMR (CDCl3) δ 7.36 (t, J = 7.2 Hz, 2H), 7.31 (t, J = 6.7 
Hz, 1H), 7.23 (d, J = 7.4 Hz, 2H), 3.86 (s, 2H), 3.44 (s, 2H), 2.59 (s, 1H), 1.70 (s, 6H). 13C NMR 
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(CDCl3) δ 200.3, 165.4, 133.3, 129.6, 129.4, 128.8, 127.3, 84.1, 73.1, 72.9, 49.9, 48.9, 28.8. HRMS 
(ESI)+ calculated for C15H16O3  [M+Na]
+: m/z 267.0997, found 267.0984. 
2f: colorless oil, yield 59%. 1H NMR (CDCl3) δ 7.40 – 7.30 (m, 3H), 7.23 – 7.18 (m, 2H), 
4.85 – 4.70 (m, 1H), 3.81 (s, 2H), 3.44 (d, J = 2.1 Hz, 2H), 2.26 (d, J = 2.3 Hz, 1H), 1.41 (d, J = 
6.9 Hz, 3H). 13C NMR (CDCl3) δ 204.3, 164.5, 132.9, 129.6, 129.0, 127.6, 83.9, 70.6, 50.8, 47.8, 
37.0, 22.1. HRMS (ESI)+ calcd for C14H15NO2 [M+H]
+ m/z 230.1176, found 230.1171. 
2g: 1H NMR (CDCl3) δ 7.41 – 7.31 (m, 3H), 7.25 – 7.10 (m, 3H), 3.82 (s, 2H), 3.44 (s, 
2H), 2.35 (s, 1H), 1.63 (s, 7H). 13C NMR (CDCl3) δ 204.7, 164.2, 132.8, 129.6, 128.9, 127.5, 86.8, 
69.2, 50.8, 48.6, 47.4, 28.9. HRMS (ESI)+ calculated for C15H17NO2  [M+Na]
+: m/z 266.1157, 
found 266.1151. 
2h: colorless oil, yield, 63%. 1H NMR (CDCl3) δ 6.97 (s, 1H), 3.56 (s, 2H), 3.30 (s, 2H), 
2.34 (s, 1H), 2.07 (s, 3H), 1.64 (s, 6H). 13C NMR (CDCl3) δ 200.8, 164.4, 86.7, 69.3, 47.5, 47.4, 
43.9, 28.9, 15.7. HRMS (ESI)+ calculated for C10H15NO2S [M+H]
+ 214.0896, found 214.0899. 
2i: colorless oil, 87%. 1H NMR (CDCl3) δ 3.61 (s, 2H), 3.31 (s, 2H), 2.56 (s, 1H), 2.04 (s, 
3H), 1.66 (d, J = 13.6 Hz, 6H). 13C NMR (CDCl3) δ 197.2, 165.3, 90.8, 73.1, 46.7, 43.0, 29.1, 15.9. 
HRMS (ESI)+ calculated for C10H14O3S [M+Na]
+ 237.0561, found: 237.0553 
General procedure B for the synthesis of BW-CO-108 – 113: To a solution of compound 
2 (1.0 mmol) in THF/MeOH (3:1, v/v, 1.6 mL), acenaphthylene-1,2-dione (1.0 mmol, 1.0 equiv.) 
and Et3N (1.5 mmol, 1.5 equiv.) were added.  The mixture was stirred at room temperature for 1 – 
2 h, after which it was concentrated under vacuum and the resulting residue was dissolved in acetic 
anhydride (2 mL). The resulting solution was cooled to 0 °C and 2-5 drops of H2SO4 was then 
added. After stirring at room temperature for 1 h, the solution was diluted with EtOAc (40 mL), 
and washed with water (20 mL) and brine (20 mL). The combined organic phase was dried over 
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anhydrous Na2SO4, and evaporated under reduced pressure. The resulting crude product was 
purified by silica gel column chromatography. The obtained crude product was dissolved in MeOH, 
and the resulting purple solution was put in a freezer overnight, leading to the formation of dark 
needle crystals, which were filtered and dried under vacuum to yield the title compound. 
BW-CO-108: purple solid, yield 77%. 1H NMR (CDCl3) δ 8.77 (d, J = 7.2 Hz, 1H), 8.02 
(dd, J = 16.2, 7.6 Hz, 2H), 7.90 (d, J = 8.2 Hz, 1H), 7.85 – 7.68 (m, 3H), 7.67 – 7.39 (m, 4H), 5.76 
(qd, J = 6.7, 2.1 Hz, 1H), 2.57 (d, J = 2.1 Hz, 1H), 1.73 (d, J = 6.7 Hz, 3H). 13C NMR (CDCl3) δ 
196.8, 170.2, 161.2, 150.8, 145.1, 131.6, 131.1, 130.5,130.3,130.0, 129.6, 129.1, 129.0, 128.6, 
128.6, 128.4, 127.8, 124.4, 121.3, 109.3, 82.3, 73.3, 60.3, 21.5. HRMS (ESI)+ calculated for 
C26H16O3 [M+H]
+ m/z 377.1172, found 377.1170. 
BW-CO-109: purple solid, yield 70% 1H NMR (CDCl3) δ 8.90 (d, J = 7.3 Hz, 1H), 8.06 
(dd, J = 10.3, 7.8 Hz, 2H), 7.94 (d, J = 8.2 Hz, 1H), 7.86 – 7.74 (m, 3H), 7.63 (t, J = 7.6 Hz, 1H), 
7.54 (t, J = 7.5 Hz, 2H), 7.46 (t, J = 7.4 Hz, 1H), 2.67 (s, 1H), 1.93 (s, 6H). 13C NMR (CDCl3) δ 
196.9, 170.3, 161.1, 150.8, 145.1, 131.6, 130.9, 130.7,130.4,130.1, 129.6, 129.0, 128.9, 128.7, 
128.6, 128.4, 127.8, 124.1, 121.3, 110.8, 85.0, 72.8, 72.5, 29.2. HRMS (ESI)+ calculated for 
C27H18O3 Na [M+Na]
+: m/z 413.1154, found 413.1146. 
BW-CO-110: purple solid, yield 59%. 1H NMR (CDCl3) δ 9.03 (d, J = 7.1 Hz, 1H), 8.04 
(t, J = 6.9 Hz, 2H), 7.94 (d, J = 8.1 Hz, 1H), 7.79 (dd, J = 14.9, 7.6 Hz, 2H), 7.59 (dt, J = 24.4, J 
= 7.5 Hz, 3H), 7.47 (t, J = 7.5 Hz, 1H), 5.18 – 4.97 (m, 1H), 2.33 (s, 1H), 1.59 (d, J = 7.0 Hz, 3H). 
13C NMR (CDCl3) δ 202.3, 160.7, 152.5, 146.1, 131.6, 130.6, 130.4, 130.3, 130.2, 129.3, 129.2, 
129.1, 128.7, 128.2, 128.1, 121.3, 111.7, 84.2, 70.2, 36.3, 22.2. HRMS (ESI)+ calculated for 
C26H17NO2 [M+H]
+ 376.1332, found 376.1329 
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BW-CO-111: purple solid, yield 59% 1H NMR (CDCl3) δ 9.06 (d, J = 6.5 Hz, 1H), 8.08 – 
7.92 (m, 3H), 7.90 (d, J = 7.7 Hz, 1H), 7.76 (t, J = 9.6 Hz, 3H), 7.62 – 7.38 (m, 4H), 2.45 (s, 1H), 
1.81 (s, 6H). 13C NMR (CDCl3) δ 202.5, 168.2, 160.8, 152.7, 146.1, 131.6, 130.4, 129.6, 129.3, 
129.0, 128.7, 128.1, 122.9, 121.2, 112.7, 87.2, 69.2, 46.9, 29.5. HRMS (ESI)+ calculated for 
C27H19NO2 [M+Na]
+: m/z 412.1313, found 412.1318. 
BW-CO-112: dark green solid, yield, 20%. 1H NMR (CDCl3) δ 8.96 (d, J = 6.8 Hz, 1H), 
7.97 (d, J = 8.4 Hz, 1H), 7.83 – 7.76 (m, 3H), 7.71 (q, J = 7.2 Hz, 1H), 7.62 (q, J = 7.2 Hz, 1H), 
2.73 (s, 3H), 2.42 (s, 1H), 1.77 (s, 6H). 13C NMR (CDCl3) δ 199.3, 168.3, 160.3, 151.2, 145.4, 
131.4, 130.6, 130.3, 130.0, 129.7, 129.1, 128.4, 126.9, 121.8, 121.4, 113.6, 87.2, 69.2, 46.9, 29.5, 
14.9. HRMS (ESI)+ calculated for [M+H]+ 360.1053, found: 360.1050. 
BW-CO-113: dark green solid, yield, 35%. 1H NMR (CDCl3) δ 8.65 (d, J = 7.2 Hz, 1H), 
7.96 (d, J = 8.1 Hz, 1H), 7.77 (d, J = 8.1 Hz, 1H), 7.68 – 7.53 (m, 3H), 2.80 (s, 3H), 2.68 (s, 1H), 
1.91 (s, 6H). 13C NMR (CDCl3) δ 193.56, 169.90, 160.34, 147.84, 144.19, 131.28, 131.05, 130.17, 
129.85, 128.87, 128.78, 128.59, 126.43, 123.78, 121.57, 110.89, 85.05, 72.79, 72.36, 29.25, 14.36. 
HRMS (ESI)+ calculated forC22H16O3S [M+Na]
+ 383.0718, found: 383.0728 
General procedure C for the intramolecular DA reactions:  A solution of compound 
BW-CO-108 – 113 (0.1 mM) in DMSO/PBS (5:1, v/v, 2mL) was incubated at 37 oC for indicated 
time. Then the reaction mixture was diluted with water, and extracted with EtOAc (25 mL). The 
combined organic layer was dried over anhydrous Na2SO4, concentrated under vacuum to afford 
the crude product, which was purified by silica gel column to afford the cyclized product BW-CP-
108 - 113. 
BW-CP-108: yellow solid, yield 90%, 1H NMR (DMSO-d6) δ 9.09 (d, J = 7.1 Hz, 1H), 
8.14 (d, J = 8.1 Hz, 1H), 8.03 (d, J = 8.1 Hz, 1H), 7.87 (t, J = 7.6 Hz, 1H), 7.69 – 7.43 (m, 7H), 
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7.15 (d, J = 7.1 Hz, 1H), 5.89 (d, J = 6.6 Hz, 1H), 1.70 (d, J = 6.6 Hz, 3H). 13C NMR (CDCl3) δ 
170.6, 150.6, 144.2, 140.0, 138.3, 138.0, 135.1, 133.7, 132.6, 129.6, 128.9, 128.8, 128.6, 128.6, 
128.3, 127.6, 127.5, 124.0, 121.2, 120.1, 78.3, 20.9. HRMS (ESI)+ calculated for C25H16O2 
[M+H]+ m/z 349.1223, found 349.1222. 
BW-CP-109: yellow solid, yield 90%. 1H NMR (CDCl3) δ 9.27 (d, J = 7.0 Hz, 1H), 7.99 
(d, J = 8.1 Hz, 1H), 7.88 (d, J = 8.1 Hz, 1H), 7.84 – 7.72 (m, 1H), 7.68 – 7.55 (m, 5H), 7.47 – 7.38 
(m, 1H), 7.25 – 7.19 (m, 2H), 1.80 (s, 6H). 13C NMR (CDCl3) δ 169.9, 154.5, 144.2, 140.1, 138.4, 
137.9, 135.1, 133.8, 132.6, 129.6, 128.8, 128.8, 128.6, 128.2, 127.6, 127.5, 123.9, 120.4, 119.7, 
85.8, 27.8. HRMS (ESI)+ calculated for C26H18O2 [M+Na]
+: m/z 385.1204, found 385.1213. 
BW-CP-110: yellow oil, yield, 93%. 1H NMR (DMSO-d6) δ 9.29 (d, J = 6.9 Hz, 1H), 8.88 
(s, 1H), 8.05 (d, J = 8.2 Hz, 1H), 7.95 (d, J = 8.2 Hz, 1H), 7.81 (t, J = 7.6 Hz, 1H), 7.62 (s, 4H), 
7.52 – 7.38 (m, 2H), 7.09 (d, J = 7.1 Hz, 1H), 4.81 (d, J = 6.6 Hz, 1H), 1.49 (d, J = 6.5 Hz, 3H). 
13C NMR (DMSO-d6) δ 169.9, 149.8, 141.7, 140.4, 136.3, 136.1, 135.7, 134.6, 132.1, 129.8, 129.3, 
129.1, 128.9, 128.8, 128.6, 128.2, 128.1, 127.7, 127.6, 123.4, 123.3, 52.8, 21.0. HRMS (ESI)+ 
calculated for C25H17NO [M
+H]+ 348.1383, Found 348.1371. 
BW-CP-111: 1H NMR (CDCl3) δ 9.37 (d, J = 6.7 Hz, 1H), 7.94 (d, J = 8.1 Hz, 1H), 7.84 
(d, J = 8.3 Hz, 1H), 7.78 (d, J = 7.0 Hz, 1H), 7.61 (m, 5H), 7.39 (t, J = 7.2 Hz, 1H), 7.24 (s, 1H), 
7.18 (d, J = 6.5 Hz, 1H), 6.22 (s, 1H), 1.68 (s, 6H). 13C NMR (DMSO-d6) δ 168.7, 154.0, 141.9, 
140.4, 136.3, 135.7, 134.6, 132.3, 129.8, 129.3, 129.2, 128.8, 128.6, 128.1, 127.7, 126.7, 123.3, 
122.3, 59.3, 28.3. HRMS (ESI)+ calculated for C26H19NO [M+Na]
+: m/z 384.1364 , found 
384.1378. 
BW-CP-112: yellow solid, yield, 96%. 1H NMR (CDCl3) δ 9.33 (d, J = 7.0 Hz, 1H), 8.50 
(d, J = 7.1 Hz, 1H), 7.94 (dd, J = 16.1, 8.1 Hz, 2H), 7.68-7.77 (m, 2H), 7.20 (s, 1H), 6.16 (s, 1H), 
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2.75 (s, 3H), 1.65 (s, 6H). 13C NMR (CDCl3) δ 169.6, 153.2, 140.2, 137.4, 135.8, 134.4, 132.4, 
129.4, 128.6, 128.5, 128.3, 127.6, 127.1, 125.2, 115.2, 59.1, 28.5, 15.3. HRMS (ESI)+ calculated 
for C21H17NOS [M+H]
+ 332.1104, found: 332.1102. 
BW-CP-113: yellow oil, yield, 95%. 1H NMR (CDCl3) δ 9.21 (d, J = 7.0 Hz, 1H), 8.50 (d, 
J = 7.1 Hz, 1H), 7.97 (dd, J = 21.8, 8.1 Hz, 2H), 7.70-7.79 (m, 2H), 7.14 (s, 1H), 2.77 (s, 3H), 1.77 
(s, 6H). 13C NMR (CDCl3) δ 169.7, 154.9, 143.3, 138.0, 136.1, 135.3, 133.6, 132.2, 129.4, 129.0, 
128.5, 128.5, 127.8, 127.5, 125.7, 117.2, 113.8, 85.5, 27.9, 15.0. HRMS (ESI)+ calculated for 
C21H16O2S [M+H]
+ 333.0944, found 333.0938. 
Synthesis of compound 4: To a solution of 2,5,8,11,14,17-hexaoxanonadecan-19-yl 4-
methylbenzenesulfonate (4.5 mmol) in anhydrous THF (25 mL), NaH (6.8 mmol, 1.5 equiv.) was 
added. The mixture was then stirred at room temperature for 1 h, followed by addition of a solution 
of methyl 2-(4-hydroxyphenyl)acetate (3, 5.9 mmol, 1.3 equiv) in THF (10 mL). The mixture was 
stirred at room temperature for another 48 h, then quenched with MeOH (10 mL) and evaporated 
under reduced pressure. The resulting residue was suspended in EtOAc (150 mL) and filtered. The 
filtrate was dried under reduced pressure and purified by silica gel column chromatography to 
afford the pure product as a yellow oil (55%). 1H NMR (CDCl3) δ 7.16 (d, J = 8.8 Hz, 2H), 6.85 
(d, J = 8.4 Hz, 2H), 4.09 (t, J = 4.8 Hz, 2H), 3.83 – 3.51 (m, 27H), 3.36 (s, 3H). 13C NMR (CDCl3) 
δ 172.3, 157.9, 130.2, 126.2, 114.7, 71.9, 70.8, 70.6, 69.7, 67.5, 59.0, 52.0, 40.3. HRMS (ESI)+ 
calculated for C22H36O9 [M+Na]
+ 467.2257, found 467.2252 
Synthesis of compound 5: To a solution of compound 4 (0.86 mmol) in THF/MeOH (4:1, 
v/v, 5 mL), LiOH (1.2 mmol, 1.4 equiv.) was added and the mixture was stirred at room 
temperature for 24 h. Then the reaction mixture was quenched with aqueous HCl solution (2M, 2 
mL) and directly evaporated under reduced pressure. The resulting residue was purified via silica 
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gel column chromatography to afford the pure product as a yellow oil (98%). 1H NMR (MeOD) δ 
7.21 (d, J = 8.3 Hz, 2H), 6.90 (d, J = 8.3 Hz, 2H), 4.18 – 4.07 (m, 2H), 3.95 – 3.83 (m, 2H), 3.77 
– 3.48 (m, 22H), 3.36 (s, 3H). 13C NMR (MeOD) δ 157.9, 130.0, 127.0, 114.3, 71.6, 70.4, 70.2, 
70.1, 70.0, 69.5, 67.2, 57.7. HRMS (ESI)+ calculated for C21H36O9 [M+H]
+ 432.2348, found 
432.2334 
Synthesis of compound 6: To a solution of compound 5 (1.5 mmol) in anhydrous DCM 
(5 mL), Meldrum’s acid (1.8 mmol, 1.5 equiv.) and DMAP (1.8 mmol, 1.5 equiv.) were added. 
The solution was cooled to 0 °C and EDC (1.8 mmol, 1.5 equiv.) was added under protection of 
argon. After stirred at 0 °C for 1 h, the solution was allowed to warm to room temperature and was 
stirred for another 6h. Then the reaction was quenched by aqueous HCl solution (1M, 10 mL) and 
extracted with EtOAc (3 × 25 ml). The combined organic phase was then dried over anhydrous 
Na2SO4, evaporated under reduced pressure. The resulting residue was purified by silica gel 
column chromatography to afford the pure product as a white solid (81%). 1H NMR (MeOD) δ7.31 
(d, J = 8.4 Hz, 2H), 6.88 (d, J = 8.0 Hz, 2H), 4.35 (s, 2H), 4.11 (d, J = 2.4Hz, 2H), 3.85 (s, 2H), 
3.71 – 3.55 (m, 20H), 3.38 (s, 3H), 1.72 (s, 6H). 13C NMR (MeOD) δ 195.0, 158.2, 130.7, 130.3, 
126.2, 114.8, 114.7, 104.9, 91.2, 71.9, 70.8, 70.6, 70.5, 70.4, 69.6, 67.4, 59.0, 40.0, 26.9. HRMS 
(ESI)+ calculated for C27H40O12 [M+Na]
+ m/z 579.2417, found 579.2423. 
Synthesis of compound 7: To a solution of compound 6 (0.43 mmol) in chlorobenzene (5 
mL), but-3-yn-2-ol (0.85 mmol, 2 equiv.) was added. After refluxed for 45 minutes, the reaction 
mixture was directly evaporated under reduced pressure to afford the crude product which was 
further purified by silica gel column chromatography to afford the pure product as a pale yellow 
oil (84%). 1H NMR (CDCl3) δ 7.08 (d, J = 8.4 Hz, 2H), 6.85 (d, J = 8.0 Hz, 2H), 5.43 – 5.39 (m, 
1H), 4.08 (t, J = 4.8, 2H), 3.82 – 3.33 (m, 30H), 2.49 (s, 1H), 1.22 (d, J = 4.8 Hz, 3H). 13C NMR 
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(CDCl3) δ 206.8, 157.9, 130.6, 130.4, 130.2, 126.5, 115.0, 114.9, 114.7, 71.9, 70.8, 70.6, 70.6, 
70.6, 70.5, 69.7, 67.5, 59.0, 50.1, 29.1.  HRMS (ESI)+ calculated for C27H40O10 [M+H]
+  m/z 
526.2767, found 526.2749. 
Synthesis of compound BW-CO-114: To a solution of compound 7 (0.43 mmol) in 
THF/MeOH (3:1, v/v, 5 mL), acenaphthylene-1,2-dione (1.1 mmol, 1.0 equiv.) and Et3N (1.4 
mmol, 1.5 equiv.) were added.  The mixture was stirred at room temperature for 1 h, after which 
it was concentrated under vacuum and the resulting residue was dissolved in acetic anhydride (2 
mL). The resulting solution was cooled to 0 °C and 2-5 drops of H2SO4 was then added. After 
stirring at room temperature for 1h, the solution was diluted with EtOAc (40 mL), and washed 
with water (20 mL) and brine (20 mL). The combined organic phase was dried over anhydrous 
Na2SO4, and evaporated under reduced pressure to afford the crude product,  which was purified 
by silica gel column chromatography to afford the title compound.1H NMR (CDCl3) δ 8.78 (d, J 
= 7.2 Hz, 1H), 8.01 (dd, J = 22.4, 7.7 Hz, 2H), 7.89 (s, 1H), 7.75 (dd, J = 18.6, 8.2 Hz, 3H), 7.59 
(t, J = 7.7 Hz, 1H), 7.07 (t, J = 12.5 Hz, 2H), 5.75 (q, J = 6.4 Hz, 1H), 4.22 (t, J = 4.7 Hz, 2H), 3.91 
(d, J = 4.7 Hz, 1H), 3.79 – 3.48 (m, 21H), 3.37 (s, 3H), 2.56 (s, 1H), 1.72 (d, J = 6.7 Hz, 3H). 13C 
NMR (CDCl3) δ 197.2, 170.9, 161.3, 159.7, 148.8, 144.9, 131.6, 131.3, 131.1, 130.6, 130.2, 128.9, 
128.6, 128.4, 127.4, 124.4, 123.2, 121.0, 114.9, 109.0, 82.4, 73.4, 72.0, 70.9, 70.7, 70.6, 70.6, 70.6, 
70.5, 69.7, 67.6, 60.3, 59.0, 21.6. HRMS (ESI)+ calculated for C39H42O10 [M+H]+ 671.2851, 
found 671.2852. 
The cyclized product BW-CP-114 was obtained according to general procedure C. 
BW-CP-114. yellow oil, yield, 62%. 1H NMR (CDCl3) δ 9.24 (d, J = 6.9 Hz, 1H), 8.00 (d, 
J = 8.1 Hz, 1H), 7.89 (d, J = 8.2 Hz, 1H), 7.80 (t, J = 7.7 Hz, 1H), 7.54 (d, J = 7.5 Hz, 2H), 7.45 
(t, J = 7.7 Hz, 1H), 7.32 (s, 1H), 7.24 (s, 1H), 7.14 (d, J = 8.0 Hz, 2H), 5.75 (dd, J = 13.2, 6.9 Hz, 
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1H), 4.30 (t, J = 4.5 Hz, 2H), 3.98 (t, J = 4.4 Hz, 2H), 3.88 – 3.50 (m, 16H), 3.39 (s, 3H), 1.76 (d, 
J = 6.5 Hz, 3H). 13C NMR (CDCl3) δ 170.5, 159.1, 150.7, 143.9, 138.2, 135.3, 133.9, 132.5, 132.3, 
130.2, 129.7, 128.7, 128.4, 128.0, 127.6, 127.3, 124.1, 121.5, 119.8, 115.1, 78.4, 72.1, 71.2, 70.3, 
69.6, 67.4, 58.9, 20.8. HRMS (ESI)+ calculated for C38H42O9 [M+H]
+ 643.2902, found 643.2910. 
General procedure D to synthesis of compound 9: To a solution of methyl 2-(2-
hydroxyphenyl)acetate (8, 20 mmol) in ACN (10 mL), K2CO3 (60 mmol, 3.0 equiv.), and 
propargyl bromide or 3-Butyn-2-yl 4-methylbenzenesulfonate (60 mmol, 2.0 equiv.) were added. 
The mixture was then heated at reflux for 4 h and allowed to recover to room temperature. The 
reaction was then quenched with aqueous HCl solution (1M, 30 mL) and extracted with DCM 
(3×30 mL). The combined organic phase was dried over anhydrous Na2SO4, and evaporated under 
reduced pressure to give the crude product which was further purified by silica gel column 
chromatography to give the title compound. 
9a: yellow oil, yield, 91%. 1H NMR (CDCl3) δ 7.26 (t, J = 7.8 Hz, 1H), 7.21 (d, J = 7.2 Hz, 
1H), 7.03 – 6.91 (m, 2H), 4.69 (d, J = 2.3 Hz, 2H), 3.68 (s, 3H), 3.66 (s, 2H), 2.50 (s, 1H). 13C 
NMR (CDCl3) δ 172.1, 155.6, 131.1, 128.5, 123.8, 121.6, 112.2, 78.6, 75.5, 56.1, 51.9, 35.8. 
HRMS (ESI)+ calculated for C12H12O3 [M+H]
+ 205.0859, found: 205.0858. 
9b: yellow oil, yield, 87%. 1H NMR (CDCl3) 
1H NMR (CDCl3) δ 7.34 (t, J = 7.8 Hz, 1H), 
7.28 (d, J = 7.4 Hz, 1H), 7.17 (d, J = 8.2 Hz, 1H), 7.04 (t, J = 7.4 Hz, 1H), 4.94 (q, J = 6.5 Hz, 1H), 
3.64-3.90(m, 5H), 2.55 (s, 1H), 1.73 (d, J = 6.5 Hz, 3H). 13C NMR (CDCl3) δ 172.3, 155.5, 131.1, 
128.4, 124.0, 121.4, 113.3, 83.0, 73.9, 63.9, 51.9, 36.2, 22.2. HRMS (ESI)+ calculated for 
C13H14O3+ [M+H]
+  219.1016, found: 219.1015. 
General procedure E for the synthesis of compound 10: To a solution of 9a or 9b (10.5 
mmol) in MeOH/H2O (1:1, 20 mL), KOH (12 mmol, 1.14 equiv.) was added. The reaction was 
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stirred at room temperature for 1 h, then quenched with aqueous HCl solution (1 M, 30 mL) and 
extracted with DCM (2 x 100 mL). The combined organic phase was dried over anhydrous Na2SO4 
and the solvent was removed in the vacuum to give the crude product, which was purified by silica 
gel column chromatography to give the title compound.  
10a: white solid, yield, 65%. 1H NMR (CDCl3) δ 7.32 – 7.24 (m, 1H), 7.22 (d, J = 7.4 Hz, 
1H), 6.96-7.03 (m, 2H), 4.72 (d, J = 2.3 Hz, 2H), 3.69 (s, 2H), 2.49 (s, 1H). 13C NMR (CDCl3) δ 
178.0, 155.8, 131.3, 128.9, 123.2, 121.7, 112.4, 78.6, 75.7, 56.3, 35.8. HRMS (ESI)+  calculated 
for C11H10O3 [M+Na]
+  213.0522, found: 213.0519. 
10b: white solid, 79%. 1H NMR (CDCl3) δ 11.66(s, 1H), 7.31 (t, J = 7.8 Hz, 1H), 7.24 (d, 
J = 7.4 Hz, 1H), 7.14 (d, J = 8.2 Hz, 1H), 7.00 (t, J = 7.4 Hz, 1H), 4.90 (d, J = 6.5 Hz, 1H), 3.60-
3.84(m, 2H), 2.50 (s, 1H), 1.68 (d, J = 6.5 Hz, 3H). 13C NMR (CDCl3) δ 178.5, 155.6, 131.2, 128.8, 
123.3, 121.5, 113.3, 82.9, 74.1, 64.1, 36.1, 22.2. HRMS (ESI)+  calculated for C12H12O3 [M+H]
+  
227.0679, found: 227.0676. 
General procedure F for the synthesis of compound 11: To a solution of 10a or 10b (6.3 
mmol) in DCM (30 mL), DMAP (6.3 mmol, 1.0 equiv.), EDC (6.9 mmol, 1.1 equiv.) and 2,2-
dimethyl-1,3-dioxane-4,6-dione (6.9 mmol, 1.1 equiv.) were added. The reaction was allowed to 
stir at room temperature for 12 h and then filtered. The filtrate was washed HCl aqueous solution 
(1 M, 10 mL) and brine (10 mL). Then the combined organic phase was dried over anhydrous 
Na2SO4 and the solvent was removed in the vacuum to give the crude product, which was purified 
by silica gel column chromatography to give the title compound. 
11a: yellow solid, yield, 56%. The tautomers make the NMR spectrum very complicated 
thus only the major peaks of enol form are reported here.  1H NMR (CDCl3) δ 15.38 (s, 1H), 7.32 
– 7.27 (m, 1H), 7.22 (d, J = 7.2 Hz, 1H), 6.97-7.01 (m, 2H), 4.68 (d, J = 2.3 Hz, 2H), 4.48 (s, 2H), 
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2.47 (s, 1H), 1.76 (s, 6H). 13C NMR (CDCl3) δ 195.8, 170.8, 160.6, 155.8, 131.5, 129.0, 123.5, 
121.8, 112.3, 105.1, 91.7, 78.5, 75.7, 56.4, 37.1, 27.0. HRMS (ESI)+ calculated for C17H16O6 
[M+Na]+ 339.0839, found: 339.0851.  
11b: yellow solid, yield, 65%. The tautomers make the NMR spectrum very complicated 
thus only the major peaks of enol form are reported here. 1H NMR (CDCl3) δ 15.38 (s, 1H), 7.16-
7.30 (m, 2H), 7.09 (d, J = 8.2 Hz, 1H), 6.97 (t, J = 7.3 Hz, 1H), 4.92 – 4.78 (m, 1H), 4.47 (d, J = 
5.1 Hz, 2H), 2.45 (s, 1H), 1.75 (d, J = 3.3 Hz, 6H). 13C NMR (CDCl3) δ 196.2, 170.8, 160.5, 155.6, 
131.5, 128.9, 123.6, 121.6, 113.3, 105.1, 91.6, 82.9, 74.1, 64.1, 37.2, 27.0, 22.3.  
General procedure G for the synthesis of compound 12: To a solution of 11a or 11b 
(2.6 mmol) in chlorobenzene (20 ml), morpholine (5.2 mmol, 2.0 equiv.) and TMSCl (7.3 mmol, 
2.8 equiv.) were added. The reaction was heated at reflux for 3 h and was allowed to warm to room 
temperature. After filtration, the solvent of the filtrate was removed in the vacuum to give the 
crude product, which was purified by silica gel column chromatography to afford the title 
compound. 
12a: yellow solid, yield, 60%. 1H NMR (CDCl3) δ 7.29 – 7.19 (m, 1H), 7.15 (d, J = 7.0 Hz, 
1H), 6.94-6.97 (m, 2H), 4.68 (t, J = 3.7 Hz, 2H), 3.76 (s, 2H), 3.66 – 3.56 (m, 8H), 3.31 – 3.25 (m, 
2H), 2.50 (t, J = 2.2 Hz, 1H). 13C NMR (CDCl3) δ 202.1, 165.5, 155.3, 131.8, 128.9, 123.4, 121.9, 
112.0, 78.4, 75.9, 66.7, 66.6, 56.0, 48.2, 46.8, 45.0, 42.1. HRMS (ESI)+ calculated for C17H19NO4 
[M+Na]+ 302.1387, found: 302.1384. 
12b: yellow solid, yield, 59%. 1H NMR (CDCl3) 7.18 (t, J = 7.3 Hz, 1H), 7.08 (d, J = 8.2 
Hz, 1H), 6.98 (s, 1H), 4.87-4.91 (m, 1H), 3.76 (q, J = 16.0 Hz, 2H), 3.69 – 3.54 (m, 8H), 3.26-
3.29(m, 2H), 2.46 (s, 1H), 1.64 (d, J = 6.5 Hz, 3H). 13C NMR (CDCl3) δ 202.4, 165.6, 155.2, 131.8, 
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129.0, 123.6, 113.2, 82.8, 74.3, 66.9, 66.7, 63.8, 48.0, 46.9, 45.5, 42.2, 22.3. HRMS (ESI)+ 
calculated for C18H21NO4 [M+H]
+  316.1543, found: 316.1541. 
The prodrug BW-CO-115 - 116 were obtained according to general procedure B. 
BW-CO-115: purple solid, yield, 36%. 1H NMR (CDCl3) δ 8.08 (d, J = 7.1 Hz, 1H), 7.95 
(d, J = 8.2 Hz, 1H), 7.85 (dd, J = 7.1, 1.7 Hz, 1H), 7.62 – 7.70 (m, 1H), 7.56-7.61(m, 2H), 7.41-
7.50 (m, 2H), 7.20 (d, J = 8.3 Hz, 1H), 7.14 (t, J = 7.5 Hz, 1H), 4.69 (d, J = 2.3 Hz, 2H), 3.83 (s, 
4H), 3.74 (d, J = 4.3 Hz, 2H), 3.57 (s, 2H), 2.50 (s, 1H). 13C NMR (CDCl3) δ 199.0, 164.4, 163.1, 
156.1, 153.7, 145.5, 131.8, 131.7, 131.4, 130.1, 129.5, 128.7, 128.7, 127.4, 125.0, 123.8, 121.6, 
120.3, 118.8, 115.5, 112.8, 78.5, 76.0, 67.5, 67.0, 56.3, 48.2, 42.9. HRMS (ESI)+ calcd for 
C29H21NO4 [M+H]
+  448.1543, found: 448.1545. 
BW-CO-116: purple solid, yield, 45%. 1H NMR (CDCl3) δ 8.09 (d, J = 7.1 Hz, 1H), 7.95 
(d, J = 8.1 Hz, 1H), 7.85 (d, J = 8.7 Hz, 1H), 7.67 (dd, J = 8.2, 7.2 Hz, 2H), 7.58 (t, J = 7.6 Hz, 
1H), 7.48 (dd, J = 7.6, 1.5 Hz, 1H), 7.45 – 7.37 (m, 1H), 7.28 (s, 1H), 7.12 (td, J = 7.5, 0.9 Hz, 
1H), 4.87 (s, 1H), 3.75-3.83 (m, 6H), 3.57 (s, 2H), 2.60 (s, 1H), 1.35 (d, J = 6.5 Hz, 3H). 13C NMR 
(CDCl3) δ 199.1, 163.1, 155.8, 153.5, 145.4, 131.8, 131.7, 131.4, 130.1, 130.0, 129.5, 128.6, 127.3, 
124.9, 121.3, 115.4, 74.6, 67.5, 67.0, 64.0, 48.2, 42.8, 22.1. HRMS (ESI)+ calcd for C30H23NO4 
[M+H]+  462.1700, found: 462.1701. 
The cyclized product BW-CP-115 and BW-CP-116 were obtained according to 
general procedure C. 
BW-CP-115: yellow solid, yield, 95%.   1H NMR (CDCl3) δ 8.49 (d, J = 7.2 Hz, 1H), 8.39 
(dd, J = 7.6, 1.5 Hz, 1H), 7.94 – 7.78 (m, 3H), 7.64 (dd, J = 8.2, 7.1 Hz, 1H), 7.61 – 7.52 (m, 1H), 
7.36-7.41 (m, 1H), 7.18-7.22 (m, 2H), 7.09 (s, 1H), 5.16 – 4.92 (m, 2H), 4.07 – 3.77 (m, 4H), 3.62 
– 3.16 (m, 4H). 13C NMR (CDCl3) δ 169.1, 156.9, 136.9, 136.3, 135.7, 135.4, 134.4, 133.0, 130.4, 
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130.3, 129.6, 129.0, 128.1, 128.0, 127.9, 127.8, 127.7, 123.9, 123.6, 122.3, 121.8, 121.1, 69.9, 
67.2, 66.9, 47.5, 42.2. HRMS (ESI)+   calcd for C28H22NO3 [M+H]
+  420.1594, found: 420.1592. 
BW-CP-116: yellow oil, yield, 93%. 1H NMR (CDCl3) δ 8.48 (d, J = 7.2 Hz, 1H), 8.37 (d, 
J = 7.7 Hz, 1H), 7.89 (t, J = 7.3 Hz, 3H), 7.64 (t, J = 7.6 Hz, 1H), 7.56 (t, J = 7.7 Hz, 1H), 7.38 (t, 
J = 7.7 Hz, 1H), 7.14-7.21 (m, 2H), 7.08 (d, J = 8.9 Hz, 1H), 5.20-5.25 (m, 1H), 5.06-5.13 (m, 
0.5H), 3.89-4.04 (m, 4H), 3.60 – 3.28 (m, 4H), 1.73 (d, J = 6.5 Hz, 1.32H), 1.62 (d, J = 6.5 Hz, 
1.62H). 13C NMR (CDCl3) δ 169.3, 155.9, 155.2, 140.4, 136.5, 135.9, 135.3, 134.3, 134.3, 133.1, 
133.0, 130.4, 130.3, 129.6, 128.1, 127.9, 127.8, 127.7, 123.9, 123.8, 123.3, 123.2, 122.2, 122.1, 
121.5, 120.6, 120.4, 118.8, 118.4, 77.5, 77.2, 76.8, 75.1, 74.8, 67.2, 66.9, 47.5, 42.2, 19.6, 19.4, 
14.3. HRMS (ESI)+   calcd for C29H23NO3 [M+H]
+  434.1751, found: 434.1751. 
Syhthesis of compound 14: To a solution of 2-(2-((tert-
Butyldimethylsilyl)oxy)ethyl)aniline (13, 8.4 mmol) and pyridine (13 mmol, 1.5 equiv.) in 
anhydrous DCM (25 mL), MsCl (13 mmol, 1.5 equiv.) was added dropwisely at 0 °C under the 
protection of argon. The reaction mixture was stirred at room temperature for 12 h, after which it 
was quenched with aqueous HCl solution (1 M, 10 mL) and extracted with EtOAc (3 × 50 ml). 
The combined organic phase was washed with brine (10 mL), dried over anhydrous Na2SO4 and 
evaporated under reduced pressure. The resulting crude product was purified by silica gel column 
chromatography to afford the final product as pale yellow solid (yield: 88%).  1H NMR (CDCl3) δ 
8.50 (s, 1H), 7.52 (d, J = 8.0 Hz, 1H), 7.29 – 7.21 (m, 1H), 7.18 – 7.10 (m, 2H), 4.01 – 3.83 (m, 
2H), 2.96 (s, 3H), 2.93 – 2.80 (m, 2H), 0.86 (s, 9H), 0.01 (s, 6H). 13C NMR (CDCl3) δ 133.4, 130.9, 
128.0, 126.0, 123.7, 66.2, 40.4, 35.9, 26.1, 18.6, 5.5. HRMS (ESI)+ calcd for C15H27NO3SSi 
[M+H]+  330.1554, found: 330.1552. 
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General procedure H for the synthesis of compound 15: To a solution of 14 (15 mmol) 
in ACN (30 mL), K2CO3 (23 mmol, 1.5 equiv.) and propargyl bromide or 3-butyn-2-yl 4-
methylbenzenesulfonate (30 mmol, 2.0 equiv.) were added. The mixture was then heated at reflux 
for 4 h and recovered to room temperature. The reaction mixture then was quenched with aqueous 
solution (1 M, 30mL) and extracted with DCM (3 x 100 mL). The combined organic phase was 
dried over anhydrous Na2SO4, and evaporated under reduced pressure. The resulting residue was 
purified by silica gel column chromatography to afford the title compound. 
15a: colorless oil, yield, 78%. 1H NMR (CDCl3) δ 7.52 (d, J = 7.8 Hz, 1H), 7.44 – 7.39 (m, 
1H), 7.38 – 7.31 (m, 1H), 7.29 – 7.22 (m, 1H), 4.73 (d, J = 17.6 Hz, 1H), 4.07 (d, J = 17.8 Hz, 1H), 
3.96 – 3.75 (m, 2H), 3.13 (d, J = 5.6 Hz, 3H), 3.13 – 3.00 (m, 1H), 2.86 (s, 1H), 2.43 (s, 1H), 0.84 
(s, 9H), -0.01 (s, 6H). 13C NMR (CDCl3) δ 140.6, 138.5, 131.4, 129.2, 128.6, 127.2, 78.9, 74.3, 
63.7, 41.5, 39.8, 34.3, 26.0, 18.5, -5.3. HRMS (ESI)+ calcd for C18H29NO3SSi [M+H]
+  368.1710, 
found: 368.1708. 
15b: colorless oil, yield, 85%. 1H NMR (CDCl3) δ 7.72 (dd, J = 7.9, 1.2 Hz, 1H), 7.50 (dd, 
J = 7.8, 1.4 Hz, 1H), 7.33-7.36 (m, 1H), 7.25-7.27 (m, 1H), 5.15-5.17 (m, 1H), 4.01 – 3.78 (m, 
2H), 3.11 (s, 3H), 3.11 – 2.88 (m, 3H), 2.55 (d, J = 2.3 Hz, 1H), 1.22 (d, J = 7.2 Hz, 3H), 0.88 (s, 
9H), 0.04 (d, J = 3.6 Hz, 6H). 13C NMR (CDCl3) δ 142.4, 134.9, 130.9, 129.1, 128.8, 126.9, 83.7, 
74.1, 63.2, 46.7, 38.2, 33.9, 26.1, 20.1, 18.4, -5.2, -5.3. HRMS (ESI)+ calcd for C19H31NO3SSi 
[M+H]+  382.1867, found: 382.1848. 
General procedure I for the synthesis of compound 16: To a solution of 15a or 15b (4.5 
mmol) in acetone (20 mL), KF (9 mmol, 2.0 equiv.) and Jones reagent (9 mmol, 2.0 equiv.) were 
added and the reaction was stirred at room temperature for 20 h. The reaction mixture was then 
quenched with water (20 mL) and extracted with DCM (3 × 50 ml). The combined organic phase 
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was dried over anhydrous Na2SO4, and evaporated under reduced pressure. The resulting residue 
was purified by silica gel column chromatography to afford the title compound. 
16a: white solid, yield, 75%. 1H NMR (CDCl3) δ 7.74 – 7.66 (m, 1H), 7.48 – 7.33 (m, 3H), 
4.69 (d, J = 18.0 Hz, 1H), 4.11-4.21 (m, 2H), 3.65 (d, J = 16.5 Hz, 1H), 3.15 (s, 3H), 2.48 (s, 1H). 
13C NMR (CDCl3) δ 176.2, 139.0, 135.3, 132.2, 129.8, 128.9, 128.5, 78.9, 74.7, 41.4, 39.2, 37.3. 
HRMS (ESI)+ calcd for C12H13NO4S [M+H]
+  268.0638, found: 368.0637. 
16b: white solid, yield, 65%. The rotamers make the NMR spectrum very complicated thus 
only the major peaks are reported here. white solid. 1H NMR (CDCl3) δ 7.82 (dd, J = 7.9, 1.3 Hz, 
1H), 7.54 (dd, J = 7.7, 1.6 Hz, 1H), 7.33-7.45 (m, 2H), 5.14-5.21 (m, 1H), 3.87 (s, 2H), 3.12 (s, 
3H), 2.60 (d, J = 2.4 Hz, 1H), 1.20 (d, J = 7.2 Hz, 3H). 13C NMR (MeOD) δ 174.9, 139.0, 136.4, 
133.0, 130.2, 130.1, 128.8, 84.3, 76.1, 54.8, 47.9, 38.4, 37.4, 20.6. HRMS calcd for C13H15NO4S 
[M+H]+  304.0614, found: 304.0600. 
General procedure J for the synthesis of compounds 17: To a solution of 16a or 16b 
(3.2 mmol) in DCM (10 mL), DMAP (3.5 mmol, 1.1 equiv.), EDC (3.5 mmol,1.1equiv.) and 2,2-
dimethyl-1,3-dioxane-4,6-dione (3.5 mmol 1.1equiv.) were added. The reaction was stirred at room 
temperature for 12 h and then filtered. The filtrate was further diluted with DCM (30 mL), washed 
with aqueous HCl solution (1 M, 15 mL) and brine (10 mL). The combined organic phase was 
dried over anhydrous Na2SO4 and the solvent was removed in the vacuum to give the crude product, 
which was purified by silica gel column chromatography to give the title compound. 
17a: white solid, yield, 78%. The tautomers made the NMR spectrum very complicated. 
Thus only the major peaks of the enol form are reported here.  1H NMR (CDCl3) δ 15.43 (s, 1H), 
7.60-7.70 (m, 1H), 7.38-7.35 (m, 3H), 4.49-4.88(m, 2H), 3.41 (s, 2H), 3.08 (s, 3H), 2.50 (s, 1H), 
1.70 (s, 6H). 13C NMR (CDCl3) δ 194.5, 170.7, 160.2, 139.1, 135.9, 131.2, 129.5, 128.6, 128.3, 
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105.3, 92.0, 78.9, 74.7, 41.2, 39.0, 37.8, 26.8. HRMS (ESI)+     calcd for C18H19NO7S [M+H]
 + 
394.0955, found: 394.0970. 
17b: white solid, yield, 53%. The tautomers made the NMR spectrum very complicated. 
Thus only the major peaks of the enol form are reported here. 1H NMR (CDCl3) δ 15.46 (s, 1H), 
7.87 (d, J = 7.6 Hz, 1H), 7.49 – 7.36 (m, 3H), 5.16-5.22 (m, 1H), 5.10 (d, J = 17.2 Hz, 1H), 4.18 
(d, J = 17.2 Hz, 1H), 3.11 (s, 3H), 2.61 (d, J = 2.4 Hz, 1H), 1.77 (s, 6H), 1.31 (d, J = 7.2 Hz, 3H). 
13C NMR (CDCl3) δ 194.5, 136.9, 135.4, 132.4, 129.3, 128.7, 128.3, 105.3, 92.3, 83.5, 74.3, 46.7, 
37.8, 37.3, 19.9.  
General procedure K for the synthesis of compounds 18: To a solution of 17a or 17b 
(1.6 mmol) in chlorobenzene (20 mL), morpholine (3.2 mmol, 2.0 equiv.) and TMSCl (4.8 mmol, 
3.0 equiv.) were added and the reaction was heated at reflux for 3 h. The mixture temperature was 
then brought to room temperature before filtration. The solvent of filtrate was concentrated in 
vacuum to give the crude product, which was purified by silica gel column chromatography to 
give the title compound. 
18a: yellow solid, yield, 62%. The tautomers made the NMR spectrum very complicated. 
Thus only the major peaks of the enol form are reported here.  1H NMR (CDCl3) δ 7.65 (d, J = 7.4 
Hz, 1H), 7.32-7.38 (m, 3H), 4.57 (d, J = 18.3 Hz, 1H), 4.11 (d, J = 17.4 `Hz, 1H), 3.97-4.33 (m, 
2H), 3.62-3.65 (m, 6H), 3.36-3.40 (m, 2H), 3.09 (s, 3H), 2.48 (s, 1H). 13C NMR (CDCl3) δ 201.3, 
165.3, 138.7, 135.4, 132.7, 129.4, 128.5, 127.9, 78.7, 74.7, 66.6, 48.5, 46.7, 45.8, 42.1, 41.3, 38.8. 
HRMS (ESI)+    calcd for C18H22N2O5S [M+H]
+  379.1322, found: 379.1317. 
18b: yellow solid, yield, 65%. 1H NMR (CDCl3) δ 7.76 (t, J = 9.5 Hz, 1H), 7.44 – 7.28 (m, 
3H), 5.09-5.13 (m, 1H), 4.22 (d, J = 17.1 Hz, 1H), 3.69 – 3.43 (m, 8H), 3.34 (d, J = 4.3 Hz, 2H), 
3.04 (d, J = 8.0 Hz, 3H), 2.59 (d, J = 2.3 Hz, 1H), 1.13 (d, J = 7.2 Hz, 3H). 13C NMR (CDCl3) δ 
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200.5, 165.6, 136.5, 134.6, 132.8, 129.2, 128.4, 128.1, 83.3, 74.4, 66.8, 66.7, 48.7, 46.7, 46.6, 44.6, 
42.1, 37.9, 19.9. HRMS (ESI)+    calcd for C19H24N2O5S [M+H]
 + 415.1298, found: 415.1323. 
The prodrug BW-CO-117 - 118 were obtained according to general procedure B. 
BW-CO-117: purple solid, yield, 54%.  1H NMR (CDCl3) δ 8.05 (d, J = 7.1 Hz, 1H), 7.99 
– 7.90 (m, 2H), 7.84 (d, J = 8.2 Hz, 1H), 7.74 – 7.60 (m, 3H), 7.52 (7.49-7.54, m, 3H), 4.48 (s, 
2H), 3.82 (s, 4H), 3.73 (s, 2H), 3.58 (s, 2H), 3.07 (s, 3H), 2.56 (s, 1H). 13C NMR (CDCl3) δ 199.0, 
162.8, 162.5, 145.6, 139.5, 132.0, 131.4, 130.7, 130.2, 130.1, 129.5, 129.4, 128.9, 128.7, 128.5, 
128.0, 124.8, 121.4, 116.2, 78.0, 74.7, 67.4, 66.9, 48.3, 42.7, 41.6, 39.1. HRMS (ESI)+ calcd for 
C30H24N2O5S [M+H]
+  525.1479, found: 525.1483. 
BW-CP-118: yellow solid, yield, 35%. 1H NMR (CDCl3) δ 8.58 – 8.40 (m, 2H), 7.96 (dd, 
J = 10.7, 5.7 Hz, 3H), 7.88 – 7.44 (m, 5H), 7.19 (d, J = 34.5 Hz, 1H), 5.43 (q, J = 6.9 Hz, 1H), 
4.29 – 3.87 (m, 4H), 3.62 – 3.23 (m, 4H), 2.42 (d, J = 19.3 Hz, 3H), 1.29-1.34 (m, 3H). 13C NMR 
(CDCl3) δ 168.8, 168.7, 141.12, 141.0, 137.0, 136.6, 136.6, 135.9, 135.5, 135.4, 134.8, 134.5, 
134.0, 134.0, 132.9, 130.6, 130.4, 130.4, 130.3, 130.2, 130.0, 128.8, 128.7, 128.6, 128.5, 128.4, 
128.3, 128.2, 128.1, 127.8, 126.9, 126.7, 123.9, 122.8, 122.5, 122.5, 121.7, 67.2, 67.0, 66.9, 55.8, 
55.5, 47.6, 47.5, 42.3, 38.0, 37.8, 21.6, 21.1. HRMS (ESI)+   calcd for C30H26N2O4S [M+H]
+  
511.1686, found: 511.1711.  
The cyclized product BW-CP-117 was obtained according to general procedure C. 
BW-CP-117: yellow oil, yield, 93%. 1H NMR (CDCl3) δ 8.47 (dd, J = 7.6, 1.5 Hz, 1H), 
8.42 (d, J = 7.2 Hz, 1H), 7.93 (d, J = 7.3 Hz, 3H), 7.81 (dd, J = 7.9, 1.2 Hz, 1H), 7.72 – 7.64 (m, 
1H), 7.62 – 7.44 (m, 3H), 7.23 (s, 1H), 5.05 – 4.66 (m, 2H), 4.04 (t, J = 4.7 Hz, 2H), 3.96 – 3.82 
(m, 2H), 3.37-3.58 (m, 4H), 2.42 (s, 3H). 13C NMR (CDCl3) δ 168.7, 137.7, 137.1, 136.2, 136.1, 
135.3, 134.0, 132.9, 130.4, 130.4, 130.2, 129.9, 129.5, 128.6, 128.5, 128.4, 128.4, 128.3, 127.8, 
42 
126.8, 123.9, 122.8, 122.4, 67.1, 66.9, 50.4, 47.5, 42.3, 38.6.  HRMS (ESI)+    calcd for 
C29H24N2O4S [M+H]
+  497.1530, found: 497.1531.  
General procedure L for the synthesis of BW-CO-108 – 113: To a solution of compound 
2 (0.5 mmol) in N-Methyl-2-Pyrrolidone (5 mL), benzil (0.5 mmol, 1 equiv.), and KOH (0.15 
mmol, 0.3 equiv.)  was stirred at room temperature for 16 h. The mixture was stirred at room 
temperature for 16 h, after which it was diluted with H2O (15 mL) and extracted with EtOAc (2 x 
30 mL). The combined organic phase was dried over anhydrous Na2SO4 and concentrated under 
vacuum. The resulting residue was dissolved in acetic anhydride (5 mL). The resulting solution 
was cooled to 0 °C and 2-5 drops of H2SO4 was then added. After stirring at room temperature for 
15 min, the solution was diluted with EtOAc (40 mL), and washed with water (20 mL) and brine 
(20 mL). The combined organic phase was dried over anhydrous Na2SO4, and evaporated under 
reduced pressure. The resulting crude product was purified by silica gel column chromatography. 
The obtained crude product was dissolved in MeOH, and the resulting purple solution was put in 
a freezer overnight, leading to the formation of dark needle crystals, which were filtered and dried 
under vacuum to yield the title compound. 
BW-CO-119: red solid, yield, 40%. 1H NMR (CDCl3): 7.40-7.38 (m, 1H), 7.30-7.25 (m, 
4H), 7.20-7.17 (m, 4H), 7.16 (m, 2H), 7.12(d, J = 7.6 Hz, 2H), 6.88 (d, J = 8.0 Hz, 2H), 4.76 (s, 
2H), 2.45 (s, 1H).  13C NMR (CDCl3) δ 195.2, 168.1, 161.6, 152.0, 132.2, 131.6, 130.3, 130.0, 
129.4, 128.9, 128.9, 128.3, 128.2, 128.2, 127.6, 116.3, 75.0, 52.1. HRMS (ESI)+ calculated for 
C28H20O3 [M+Na]+: m/z 427.1310, found 427.1315. 
BW-CO-120: red solid, yield, 42%.  1H NMR (CDCl3): 7.35-7.37 (m, 1H), 7.35-7.30 (m, 
4H), 7.26-7.20 (m, 4H), 7.20-7.18 (m, 2H), 7.12 (m, 2H), 6.89 (d, J = 8.0 Hz, 2H), 5.49-5.54 (m, 
1H), 2.42 (s, 1H), 1.41 (d, J = 6.4 Hz, 3H).  13C NMR (CDCl3) δ 195.2, 167.2, 161.3, 152.0, 132.2, 
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131.7, 130.3, 129.9, 129.9, 129.4, 128.9, 128.8, 128.3, 128.2, 128.2, 127.9, 127.6, 116.8, 81.8, 
73.1, 60.4, 21.0. HRMS (ESI)+ calculated for C27H18O3 [M+H]
+: m/z 391.1329, found 391.1328.      
BW-CO-121: red solid, yield, 35%.  1H NMR (CDCl3): 7.35-7.21 (m, 11H), 7.04 (d, J = 
7.2 Hz, 2H), 6.93 (d, J = 7.6 Hz, 2H), 3.92-3.95 (m, 1H), 3.00-3.60 (m, 2H), 2.30-2.60 (m, 2H), 
1.79 (s, 3H), 1.29-0.86 (m, 6H). 13C NMR (CDCl3) δ 196.9, 164.4, 155.8, 152.6, 132.5, 131.9, 
130.3, 130.0, 129.7, 129.4, 128.9, 128.8, 128.6, 128.1, 128.0, 127.8, 126.6, 124.1, 76.6, 50.4, 40.4, 
21.1, 20.2, 18.4, 3.5. HRMS (ESI)+ calculated for C32H29NO2 [M+H]
+: m/z 460.2271, found 
460.2270. 
The cyclized products BW-CP-119 - 121 were obtained according to general 
procedure C. 
BW-CP-119: yellow solid, yield, 85%. 1H NMR (CDCl3): 7.56 (s, 1H), 7.20-7.22 (m, 6H), 
7.10 – 7.13 (m, 4H), 6.97-6.99 (m, 3H), 6.79-6.81 (m, 2H), 5.39 (s, 2H). 13C NMR (Acetone-d6) δ 
168.8, 147.6, 147.1, 141.4, 141.4, 141.2, 138.4, 136.0, 131.5, 130.3, 129.6, 127.7, 127.0, 127.0, 
126.9, 126.7, 126.1, 123.3, 122.0, 67.9. HRMS (ESI)+ calculated for C26H18O2 [M+H]
+: m/z 
363.1380, found 363.1376 
BW-CP-120: white solid, yield, 95%.  1H NMR (CDCl3): 7.49 (s, 1H), 7.20 (br s, 6H), 
7.12-7.11 (m, 4H), 7.07-7.12 (m, 3H), 6.81-6.77 (m, 2H), 5.59-5.64 (m, 1H), 1.76 (d, J = 6.4 Hz, 
1H). 13C NMR (CDCl3) δ 169.0, 150.9, 147.9, 141.9, 141.7, 140.9, 137.9, 135.4, 131.5, 130.2, 
129.6, 127.9, 127.3, 127.2, 126.3, 122.3, 122.1, 75.8, 20.7. HRMS (ESI)+ calculated for C27H20O2 
[M+Na]+: m/z 399.1361, found 399.1374. 
BW-CP-121: yellow solid, yield, 95%.   1H NMR (CDCl3) δ 7.21 – 6.89 (m, 10H), 6.81 
(dd, J = 7.2, 4.5 Hz, 3H), 6.70 – 6.60 (m, 2H), 4.90 (dt, J = 13.6, 6.8 Hz, 1H), 3.61 – 3.47 (m, 2H), 
3.07 – 2.89 (m, 2H), 2.10 (s, 3H), 1.16 (d, J = 6.8 Hz, 6H). 13C NMR (CDCl3): 163.4, 144.2, 141.7, 
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141.0, 140.7, 140.3, 139.8, 137.5, 131.7, 131.1, 129.9, 129.6, 129.0, 127.5, 126.6, 126.4, 126.2, 
125.5, 125.1,43.3, 38.3, 27.6, 19.9, 17.3. HRMS (ESI)+ calculated for C31H29NO [M+H]
+: m/z 
432.2322, found 432.2319. 
1.3.3 Experimental procedure for the CO detecting using a house-hold CO detector 
BW-CO-113, 117 or 121 (~10 mg) were prepared in a solution of DMSO/PBS (4:1, 10 
mL) and the solution was kept in a sealed 250 mL desiccator together with the CO detector (Drager 
Pac 7000). After 30 minutes, the detector begun to beep because of CO levels exceeding the alarm 
threshold (35 ppm).  
1.3.4 Experimental procedure for Myoglobin-CO assay 
CO release from compounds BW-CO-113, BW-CO-117 and BW-CO-121 was confirmed 
by the myoglobin-CO assay. The reported “Two compartment” myoglobin-CO assay system was 
employed here.51 A myoglobin solution in PBS (0.01 M, pH = 7.4) (1.7 mg/mL, 2.9 mL) was 
degassed by bubbling with nitrogen for at least 20 min and a freshly prepared solution of sodium 
dithionite (17mg/mL, 300 μL) was added to the myoglobin solution. Then the CO prodrug (1 mM) 
was added to the inner vial. After incubation for 1 h (BW-CO-113), 2 h (BW-CO-117) and 30 
min (BW-CO-119) at 37 oC, respectively, the solution was cooled in an ice bath for 10 min to 
increase the solubility of CO in water and the UV absorption spectra was recorded (Figure 1.10-
1.12). 
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Figure 1.9 UV–Vis spectra demonstrating the conversion of deoxy-Mb to carbon 
monoxide myoglobin (MbCO) (BW-CO-113). 
 
 
Figure 1.10 UV–Vis spectra demonstrating the conversion of deoxy-Mb to carbon 
monoxide myoglobin (MbCO) (BW-CO-117). 
 
 
Figure 1.11 UV–Vis spectra demonstrating the conversion of deoxy-Mb to carbon 
monoxide myoglobin (MbCO) (BW-CO-119). 
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1.3.5 Experimental procedure for the CO release rate study of BW-CO-108-121 
All the CO prodrugs were dissolved in in DMSO/PBS (pH 7.4, 4:1) to a final concentration 
of 100 μM. The CO release was monitored by fluorescent intensity at 450 nm for BW-CO-108- 
117. For CO prodrugs with scaffold III, the CO release was determined by the decrease of UV 
absorbance at 360 nm.  Each experiment was repeated three times independently. 
1.3.6 Experimental procedure for cytotoxicity study of CO prodrugs and corresponding 
products 
Raw 264.7 cells were seeded in 96-well plates and cultured in Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 1% 
penicillin/streptomycin at 37 °C under 5% CO2 for 24 h. Then RAW 264.7 cells were incubated 
in DMEM containing vehicle (1% DMSO) and compounds (0 – 100 µM) for 24 hours. After 
removal of the median, 150 µL of DMEM containing 10 µL CCK-8 was added to each well and 
then the cells were incubated for another three hours at 37 °C. The absorbance at 450 nm was then 
measured by using a Perkin Elmer 1420 multi-label counter. The cell viability was measured, and 
the results were normalized to the vehicle group. The experiment was triplicated, and the results 
are expressed as mean ± SEM (n = 3).  
 
Figure 1.12 The cytotoxicity of CO prodrugs to RAW264.7 after 24h incubation. 
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Figure 1.13 The cytotoxicity of inactive products of CO prodrugs to RAW264.7 after 24h 
incubation. 
 
1.3.7 Experimental procedure for intracellular CO release study of BW-CO-109, 117 and 
119 
All the experiments were duplicated to confirm the CO release in the cell environment. 
Raw 264.7 cells were seeded on coverslips in 6-well plates one day before the experiment. CO 
prodrug was dissolved in DMSO and added into the cell culture media to give different final 
concentrations (25, 50 μM) with 1% DMSO. For BW-CO-119, the cells were co-treated with BW-
CO-119 and COP-1 (CO fluorescent probe). The cells were incubated with the compound for 4 h 
at 37 °C. After that, the cells were washed with PBS twice and fixed with 4% paraformaldehyde 
for 30 minutes at room temperature. The cells were then washed with PBS again twice and the 
coverslips with cells were immersed in DI water. The coverslips were mounted onto glass slides 
using the mounting media without DAPI (ProLong® Live Antifade Reagent; P36974). The 
fluorescent imaging was performed on a Zeiss fluorescent microscope, using DAPI (BW-CO-
109/117)/FITC (BW-CO-119) imaging channel. The concentration-dependent images were taken 
using the oil objective. 
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1.3.8 Experimental procedure for computation of electron density distributions 
All calculations were performed using the Gaussian 09 program.52, 53 Initial geometry 
optimizations were carried out by DFT calculations with the use of B3LYP54 and the standard 6-
31G* basis set. HF/6-31G* calculation was used to generate the electrostatic potential. Partial 
charges were produced fitting to the electrostatic potential at points selected according to the Merz-
Singh-Kollman scheme.55, 56 All calculations were conducted on Georgia State University cluster 
Orion with 4 CPU cores.57  
 
Figure 1.14 Computational studies of charge distributions. 
 
1.4 Conclusion 
In conclusion, CO prodrugs of different structural scaffolds were designed and synthesized, 
and their CO release rates were also determined. The CO release rate of these prodrugs is readily 
tunable with half-lives ranging from minutes to hours and even days. The structure-CO release 
rate relationships are summarized in Figure 1.10. Generally, entropic factors that each tethering 
linker imposes on the system seem to play very critical roles in determining the CO release rate. 
The more rigid tethering linkers, gem-dimethyl group and 5-membered ring formation favor the 
cycloaddition reaction, and hence increase CO release rate. Apart from entropic factors, other 
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factors could also be used to tune the CO release rate. For example, the presence of two phenyl 
rings at R2 positions also substantially increased CO release rate. The understanding of the 
structure-CO release rate relationships achieved should allow us to further tune CO release rate 
and optimize our CO prodrugs. This study also provides a diverse group of CO-prodrugs for 
biology studies to examine the relationship among release rates, CO concentration, and efficacy 
and biological responses. 
 
Figure 1.15 A summary of the relationship between structure and CO release rate. 
 
1.5 Statements 
The much of the results in this chapter has been published in Chem. Eur. J. (Pan, Z.; 
Chittavong, V.; Li, W.; Zhang, J.; Ji, K.; Zhu, M.; Ji, X.; Wang, B. Organic CO Prodrugs: 
Structure-CO-Release Rate Relationship Studies. Chem. Eur. J. 2017, 23, 9838-9845.). In this 
chapter, Wang, B conceived the initial idea, and supervised the study. I and Ji, X co-designed the 
CO prodrug and perform the study.  Chittavong, V and Li, W conducted studies of the reaction 
kinetics and some of the synthesis. Zhuang, J and Ji, K conducted the in vitro biology studies. 
Zhu, M carried out the computational work. 
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2 ORGANIC CO PRODRUGS ACTIVATED BY ENDOGENOUS ROS 
2.1 Introduction 
Reactive oxygen species (ROS) are normal byproducts of aerobic metabolism in the 
process of mitochondrial oxidative phosphorylation. ROS includes free radicals such as superoxide 
anion (O2
-), hydroxyl radical (•OH), and nonradical molecules like hydrogen peroxide (H2O2), 
singlet oxygen (1O2), and so forth.
58 When the intracellular level of ROS is higher than the level 
of antioxidant species, oxidative stress occurs. Oxidative stress has been reported to directly or 
indirectly damage nucleic acids, proteins and lipids in the progress of many diseases including 
carcinogenesis, neurodegeneration atherosclerosis and diabetes.59-61 
In the CO delivery field, there is a strong interest in controlled release, and possibly 
targeting.62-64 For example, a few triggered release mechanisms (e.g. photo,34, 65-70 oxidation-70 and 
enzyme-triggered release,28 among others) have been reported. Among CO’s therapeutic 
indications, cancer, bacterial infection and inflammation are the most widely investigated, and CO 
has been firmly established as a promising therapeutic agent against these diseases. Notably, these 
diseases are all associated with elevated levels of ROS.59, 71 Therefore, it is highly desirable to 
devise CO prodrugs with a ROS-sensitive trigger for targeted delivery to these disease sites. 
However, ROS-sensitive CO delivery is a severely under-explored area, especially in ROS-
triggered metal-free CO release. In this contribution, we describe a new strategy for metal-free CO 
prodrugs with a ROS-sensitive trigger, which release CO in response to elevated intracellular ROS 
levels, sensitize cancer cells to Dox treatment, and are amenable to structural modification to serve 
different purposes (e.g. targeting). 
Previously, we have successfully developed a series of metal-free CO prodrugs using inter- 
and intra-molecular Diels-Alder cycloaddition to trigger CO release.41, 72 It was found that the 
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initial cycloaddition intermediate I (Figure 2.1) is extremely unstable, and would undergo 
cheletropic/retro-DA reaction to release CO spontaneously under very mild conditions. 
Interestingly, its structural analogue III with a single bond between C5 and C6 (Figure 2.1) is quite 
thermally stable and can be isolated without the extrusion of CO.73 Therefore, we reasoned that 
compounds with scaffold III are potential CO prodrugs, provided that a double bond between C5 
and C6 can be easily formed under physiological conditions. In doing so, an additional R7 group 
(Compound IV, Figure 1) has to be appended at either the C5 or C6 position for the intended 
elimination reaction to form compound I for CO release. In order to achieve selective CO release 
in response to an endogenous stimulus, R7 group must meet several prerequisites. First, it has to 
be chosen from poor leaving groups to render compound IV inactive for CO release, and thereby 
allows for the preparation and storage of such CO prodrugs without stability issues. Second, R7 
has to be easily transformed into a good leaving group (LG) in the presence of an endogenous 
stimulus (e.g. elevated ROS) to yield compound V, which would elicit an elimination reaction to 
afford the unstable intermediate I for CO release. 
 
Figure 2.1 A schematic illustration of the general strategy for stimulus-triggered CO 
prodrugs. 
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2.2 Results and discussion 
2.2.1 Design of reactive oxygen species (ROS) sensitive CO prodrugs 
To establish the proof-of-concept, we designed and synthesized two potential CO prodrugs 
BW-OTCO-101-102 with R7 being a phenylselenyl group for selective CO release in response to 
ROS (Scheme 2.1). The rationale underlying the choice of a phenylselenyl group is three-fold. 
First, phenylselenyl group is not a good leaving group, and hence BW-OTCO-101-102 can be 
sufficiently stable for synthesis, purification and storage. Second, it is well-established that 
phenylselenyl group is very prone to ROS oxidation74, and the formed selenoxide analogue readily 
undergoes syn-elimination (selenoxide elimination)75, leading to double bond formation between 
the C5 and C6 positions for the subsequent cheletropic reaction to release CO under very mild 
conditions. Therefore, the ligation of a phenylselenyl group would allow for CO release to disease 
site with an elevated ROS level. Last, selenium is an essential trace element in mammalian system 
with a concentration of around 1 M in serum of healthy adults76, In addition, selenium containing 
compounds have been demonstrated to be sufficiently safe for drug development, and some have 
entered clinical trials.77 In our case, the selenium containing by-product after CO release is 
phenylselenenic acid (Figure 2.2), which has been demonstrated to be relatively safe with a LD50 
value of 1200 µmol/kg in mice.78, 79 Therefore, the introduction of a phenylselenyl group would 
not raise additional cytotoxicity concerns. Consequently, phenylselenyl group was chosen to 
achieve a balance between stability and triggered CO release. 
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Scheme 2.1 The synthesis of ROS sensitive CO prodrugs. 
 
2.2.2 Synthesis of ROS sensitive CO prodrugs 
As shown in Scheme 2.1, the synthesis of BW-OTCO-101-102 was readily achieved using 
a one-step DA reaction between compound 1a/b and 2. Meanwhile, a control compound BW-
OTCO-103 (X = CH2), which would undergo selenoxide elimination without CO release, was also 
prepared. 
2.2.3 Kinetics study of ROS sensitive CO prodrugs 
With these compounds in hand, we set out to study their CO release profiles in the 
absence/presence of ROS using HPLC to monitor the consumption of BW-OTCO-101/102 and 
the formation of BW-OTCP-101/102. Initially, BW-OTCO-102 was employed to screen its 
sensitivity towards various ROS. BW-OTCO-102 is relatively more reactive toward hypochlorite 
(ClO-), singlet oxygen (1O2) and O2
−, with hypochlorite being the most reactive trigger. For 
example, the transformation from BW-OTCO-102 (20 M) to BW-OTCP-102 completed in 30 
min in the presence of hypochlorite (40 M) at 37 oC, and no formation of BW-OTCP-102 was 
observed in the absence of hypochlorite even after 48 h of incubation. Other ROS, such as 
hydrogen peroxide (H2O2, 1 mM), hydroxyl radical (HO⋅, 500 M), tert-butyl hydroperoxide 
(TBHP, 500 M) and tert-butoxy radical (tBuO⋅, 500 M) only yield less than 5% transformation 
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within 30 min. CO release in the presence of hypo-chlorite was further confirmed by a widely-
accepted CO-myoglobin assay. 
 
Figure 2.2 The CO release kinetics of BW-OTCO-101 (A) and 102 (B) in response to 
ClO- at 37 oC.  
 
     Hypochlorite is a major ROS species generated by immune cells in response to bacterial 
infection or other forms of inflammation80, and it has also been employed as a stimulus to trigger 
the release of the payload from a drug delivery system.81 In our experiments, it was also the most 
effective in triggering CO release. Therefore, we employed hypochlorite to study the CO release 
kinetics of BW-OTCO-101/102 (Figure 2.2). As shown in Figure 2.2, both BW-OTCO-101 and 
102 could undergo selenoxide elimination to form BW-OTCP-101/102 (20 M) for CO release 
in the presence of hypochlorite (40 and 60 µM) at 37 oC. In the case of BW-OTCO-101 (Figure 
2.2A), the oxidation step is quite fast (e.g. finished in 30 seconds with an initial hypochlorite 
concentration of 40 µM), and the accumulation of intermediate 3 (a mixture of diastereomer) was 
observed. However, the selenoxide elimination is quite sluggish with a half-life of around 4 h. In 
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contrast, the oxidation step is the rate limitation step for BW-OTCO-102, and intermediate 3 was 
not observed under the HPLC conditions used, indicating a spontaneous selenoxide elimination 
step. Nevertheless, BW-OTCO-102 presented much faster CO release kinetics with a half-life of 
only around 30 seconds in the presence of 40 µM hypochlorite, as com-pared to 4 h for BW-
OTCO-101 under the same conditions. 
2.2.4 Detection of intracellular CO release  
Having confirmed that BW-OTCO-101/102 could specifically release CO in response to 
ROS in vitro, we next probed if such CO prodrugs could release CO in response to elevated 
intracellular ROS levels. Towards this end, BW-OTCO-102 was tested for its intracellular CO 
release under various cellular conditions. Therefore, we conducted two types of comparative 
studies. First, it is commonly believed that cancer cells have elevated levels of ROS because of its 
rapid metabolism. Thus, we compared CO release in Hela (cancerous cells) and H9C2 cells 
(normal cells). Second, inflammatory responses are known to be associated with elevated levels 
of ROS. Therefore, a macrophage cell line (Raw264.7) was used with or without LPS stimulation, 
which is known to trigger inflammatory responses. CO production was monitored by a known 
fluorescent probe COP-1. As expected, Raw 264.7 cells co-treated with BW-OTCO-102, COP-1 
and LPS (1 g/mL) showed significantly enhanced green fluorescence (Figure 2.3g) compared to 
the control cells treated with COP-1 and BW-OTCO-102 without the stimulation of LPS (Figure 
2.3e). Similarly, Hela cells co-treated with BW-OTCO-102 and COP-1 also showed much 
enhanced green fluorescence (Figure 2.3o) compared with H9C2 cells under the same conditions 
(Figure 3k). To firmly establish the connection between CO release and elevated levels of ROS, 
we determined the relative ROS levels in these cell lines using a widely employed ROS probe.82 
LPS challenged Raw264.7 or Hela cells indeed possessed much higher ROS levels as compared 
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to Raw264.7 cells without LPS or H9C2 cells, respectively. Altogether, these results firmly 
established the capacity of BW-OTCO-102 in selective delivery of CO to disease sites with 
elevated ROS levels.  
  
Figure 2.3 Fluorescent imaging of CO release of BW-OTCO-102 in different type of 
cells.  
(a-h: Raw264.7 cells; i-l: H9C2 cells; m-p: Hela cells): a) COP-1 only (1 M); c)  LPS (1 g/mL) 
+ COP-1 (1 M); e) BW-OTCO-102 (50 M) + COP-1 (1 M); g) BW-OTCO-102  (50 M) + 
COP-1 (1 M) + LPS (1 g/mL); i) COP-1 only (1 M); k) COP-1 (1 M) + BW-OTCO-102  (50 
M); m) COP-1 only (1 M); o) COP-1 (1 M) + BW-OTCO-102  (50 M). 
 
2.2.5 Synergistic effects of CO and doxorubicin (Dox) 
Having confirmed that BW-OTCO-102 could selectively deliver CO in response to 
elevated intracellular ROS levels, we next set out to probe whether such CO prodrugs could 
recapitulate CO’s synergistic effects with Dox in killing cancer cells. Towards this end, Hela cells 
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and H9C2 cells were co-treated with BW-OTCO-102 and Dox for 24 h. Then the cells were 
subjected to the crystal violet assay for cytotoxicity evaluation. The cells treated with BW-OTCO-
102 or Dox only were used as controls. Additionally, the cells co-treated with Dox and compound 
BW-OTCO-103/BW-OTCP-102 were employed as additional controls as well. The results are 
summarized in Figure 2.4. BW-OTCO-102 inhibited the proliferation of Hela cells synergistically 
with Dox. For example, after 24 h of exposure with 2 M of Dox, the cell viability only decreased 
to around 80%, and yet this number went down to around 20% when Dox was used in combination 
with BW-OTCO-102 (12.5 M). As controls, no decrease in cell viability was observed with the 
treatment of BW-OTCO-102 only (Figure 2.4, the red and green columns in the 0-M group). In 
addition, no synergistic effects were observed between Dox and the control compound BW-
OTCO-103 or the inactive compound BW-OTCP-102 after CO release. Taken together, it can be 
confirmed that the observed synergistic effects were indeed attributed to the CO release from BW-
OTCO-102.  
2.3 Experimental Section 
2.3.1 General information 
All reagents and solvents were of reagent grade and were purchased from Aldrich. 1H-
NMR (400 MHz) and 13C-NMR (100 MHz) spectra were recorded on a Bruker Avance 400 MHz 
NMR spectrometer.  Mass spectral analyses were performed on an ABI API 3200 (ESI-Triple 
Quadruple). Compounds 2a and 2b were synthesized according to literature methods.83, 84 
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2.3.2 Experimental procedure for the synthesis of ROS-activated CO prodrugs 
 
Scheme 2.2 Synthesis of BW-OTCO-101/102 and their products 
Reagents and conditions: (i) toluene, reflux, 12 h; (ii) NaClO (100 mM) in DMSO/PBS(1:5), 37 
oC;  
 
General procedure A for the synthesis of BW-OTCO-101 and 102  
A solution of 2, 5-dimethyl-3, 4-diphenylcyclopenta-2, 4-dien-1-one (1, 1.0 mmol) and 
compound 2a/b (1.0 mmol) in toluene (10 mL) was heated under reflux for 12 h. Then the reaction 
mixture was concentrated under vacuum, and the residue was directly purified on a silica gel 
column to afford the desired product. 
1,4-Dimethyl-2,3-diphenyl-5-(phenylselanyl)bicyclo[2.2.1]hept-2-en-7-one (BW-OTCO-
101):  The title compound was synthesized according to general procedure A with compound 1 
(260 mg, 2.0 mmol) and phenyl(vinyl)selane (2a, 183 mg, 1.0 mmol) in toluene (10 mL) at 110 °C 
for 12h. Then the reaction mixture was concentrated under vacuum, and the residue was directly 
purified on a silica gel column (hexane: EtOAc = 15:1) to afford the desired product BW-OTCO-
101 as yellow oil in 53% yield (235 mg).  1H NMR (CDCl3): δ 7.59 – 7.48 (m, 2H), 7.31 – 7.21 
(m, 10H), 7.14 – 6.97 (m, 3H), 3.78 (dd, J = 9.3, 5.3 Hz, 1H), 2.59 (dd, J = 13.0, 9.3 Hz, 1H), 2.08 
(dd, J = 13.0, 5.3 Hz, 1H), 1.32 (s, 3H), 1.28(s, 3H). 13C NMR (CDCl3): δ 204.2, 144.8, 142.1, 
134.6, 134.5, 134.0, 133.8, 130.6, 130.1, 129.3, 129.2, 129.1, 129.0, 128.1, 127.8, 127.5, 127.4, 
127.1, 58.4, 53.2, 46.4, 41.8, 12.0, 11.8. HRMS (ESI)+ calcd for C27H24NaOSe [M+Na]
 + 467.0885, 
found: 467.0899. 
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Methyl-1,4-dimethyl-7-oxo-5,6-diphenyl-2-(phenylselanyl)bicyclo[2.2.1]hept-5-ene-2-
carboxylate (BW-OTCO-102):  The title compound was synthesized according to general 
procedure A with compound 1 (520 mg, 2.0 mmol) and methyl 2-(phenylselanyl)acrylate (2b, 480 
mg, 2.0 mmol) in toluene (15 mL) at 110 °C for 12h. Then the reaction mixture was concentrated 
under vacuum, and the residue was directly purified on a silica gel column (hexane:EtOAc = 10:1) 
to afford the desired product BW-OTCO-102 as white solid in 67% yield (671 mg). 1H NMR 
(CDCl3): δ 7.58 – 7.52 (m, 2H), 7.44 – 7.37 (m, 1H), 7.34 (t, J = 7.3 Hz, 2H), 7.22 – 7.10 (m, 6H), 
6.88-6.95 (m, 4H), 3.34 (s, 3H), 3.00 (d, J = 13.6 Hz, 1H), 2.11 (d, J = 13.6 Hz, 1H), 1.74 (s, 3H), 
1.20 (s, 3H). 13C NMR (CDCl3): δ 203.4, 172.7, 147.4, 139.8, 137.2, 134.2, 133.7, 129.6, 129.3, 
129.2, 128.8, 128.0, 127.8, 127.5, 127.2, 60.1, 55.0, 52.2, 51.8, 43.9, 11.6, 11.3. HRMS (ESI)+ 
calcd for C29H26NaO3Se [M+Na]
 + 525.0939, found: 525.0941. 
 
General procedure B for the synthesis of BW-OTCP-101-102  
To a solution of compound BW-OTCO-101/102 (1.0 mmol) in DMSO/PBS (10/1, 3 mL) 
was added an aqueous solution of NaClO (1M, 0.3 mL). The resulting solution was stirred at 37 
°C until the complete consumption of the starting material as indicated by TLC. The reaction 
mixture was then quenched with water (20 mL) and extracted with CH2Cl2 (3 × 50 ml). The 
combined organic phase was dried over anhydrous Na2SO4, and concentrated under reduced 
pressure. The resulting residue was purified on a silica gel column to afford the title compound. 
Methyl 3',6'-dimethyl-[1,1':2',1''-terphenyl]-4'-carboxylate (BW-OTCP-101): The title 
compound was synthesized according to general procedure B with BW-OTCO-101 (443 mg, 1.0 
mmol) and an aqueous NaClO solution (1M, 0.3 mL) in a solution of DMSO/PBS (10/1, 3 mL) at 
37 °C for 1h. The reaction mixture was then quenched with water (20 mL) and extracted with 
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CH2Cl2 (3 × 50 ml). The combined organic phase was dried over anhydrous Na2SO4 and 
concentrated under reduced pressure. The resulting residue was purified on a silica gel column 
(hexane:EtOAc = 20:1) to afford the desired product BW-OTCP-101 as white solid in 97% yield 
(250 mg). 1H NMR (CDCl3): δ 7.76 (s, 1H), 7.20 – 7.02 (m, 6H), 6.93 (t, J = 7.4 Hz, 4H), 3.96 (s, 
3H), 2.27 (s, 3H), 2.11 (s, 3H).  13C NMR (CDCl3): δ 169.0, 145.0, 143.1, 140.4, 140.2, 134.6, 
133.5, 130.3, 130.1, 129.9, 129.5, 127.5, 126.2, 126.2, 52.0, 20.7, 18.7. HRMS calcd for C22H20O2 
[M+H]+ 317.1536; found 317.1541. 
 
3',6'-Dimethyl-1,1':2',1''-terphenyl (BW-OTCP-102): The title compound was 
synthesized according to general procedure B with BW-OTCO-102 (500 mg, 1.0 mmol) and an 
aqueous NaClO solution (1M, 0.3 mL) in a solution of DMSO/PBS (10/1, 3 mL) at 37 °C for 24 
h. The reaction mixture was then quenched with water (20 mL) and extracted with CH2Cl2 (3 × 50 
ml). The combined organic phase was dried over anhydrous Na2SO4 and concentrated under 
reduced pressure. The resulting residue was purified on a silica gel column (Hexane: EtOAc = 
20:1) to afford the desired product BW-OTCP-102 as white solid in 91% yield (288 mg). 1H NMR 
(CDCl3): δ 7.26 (s, 2H), 7.21 – 7.15 (m, 4H), 7.10-7.14 (m, 2H), 7.00-7.03 (m, 4H), 2.15 (s, 6H). 
13C NMR (CDCl3): δ 141.4, 140.8, 133.5, 130.0, 128.8, 127.4, 125.9, 20.9. HRMS calcd for C20H19 
[M+H]+ 259.1481; found 259.1477. 
 
 
Scheme 2.3 Synthesis of BW-OTCO-103 and BW-OTCP-103 
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Reagents and conditions: i) toluene, reflux, 12 h; ii) NaClO, DMSO/PBS, 37 oC. 
 
Synthesis of methyl 1,4-dimethyl-5,6-diphenyl-2-(phenylselanyl)bicyclo[2.2.1]hept-5-ene-
2-carboxylate (BW-OTCO-103): To a solution of (3,5-dimethylcyclopenta-2,5-diene-1,2-
diyl)dibenzene (1a, 1.0 mmol, 245 mg) in toluene (10 mL), was added compound 2a (1.0 mmol, 
242 mg).  The mixture was heated under reflux for 12 h, after which the reaction mixture was 
concentrated under vacuum, and the residue was directly purified on a silica gel column to afford 
the desired product as colorless oil (235 mg, yield: 48%). 1H NMR (CDCl3): δ 7.57 – 7.61 (m, 
2H), 7.29 – 7.38 (m, 3H), 7.17 – 7.05 (m, 6H), 6.86 – 6.94 (m, 4H), 3.03 (s, 3H), 2.97 – 2.91 (m, 
1H), 2.35 (d, J = 8.6 Hz, 1H), 2.22 (d, J = 13.1 Hz, 1H), 1.85 (dd, J = 8.6, 3.1 Hz, 1H), 1.78 (s, 
3H), 1.18 (s, 3H).  13C NMR (CDCl3): δ 173.6, 151.0, 142.1, 136.8, 136.3, 135.6, 130.1, 129.2, 
128.9, 128.7, 128.1, 127.7, 127.4, 126.4, 62.5, 61.5, 60.1, 51.0, 50.8, 48.9, 18.2, 17.7. HRMS calcd 
for C29H29O2Se [M+H]
+ 489.1327; found 489.1364. 
Methyl 1, 4-dimethyl-5,6-diphenylbicyclo[2.2.1]hepta-2,5-diene-2-carboxylate (BW-
OTCP-103): The title compound was synthesized according to general procedure B with BW-
OTCO-103 (480 mg, 1.0 mmol) and an aqueous NaClO solution (1M, 0.2 mL) in a solution of 
DMSO/PBS (10/1, 2 mL) at 37 °C for 3 h. The reaction mixture was then quenched with water 
(20 mL) and extracted with CH2Cl2 (3 × 50 ml). The combined organic phase was dried over 
anhydrous Na2SO4 and concentrated under reduced pressure. The resulting residue was purified 
on a silica gel column (hexane:EtOAc = 20:1) to afford the desired product BW-OTCP-103 as 
colorless in 93% yield (307 mg). 1H NMR (CDCl3): δ 7.63 (s, 1H), 7.10 – 7.25 (m, 7H), 6.96 – 
6.90 (m, 2H), 3.81 (s, 3H), 2.38 (d, J = 6.5 Hz, 1H), 2.29 (d, J = 6.5 Hz, 1H), 1.60 (s, 3H), 1.41 (s, 
3H). 13C NMR (CDCl3): δ 165.6, 161.2, 155.1, 152.2, 150.2, 136.6, 135.8, 128.3, 128.3, 127.9, 
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127.8, 126.6, 126.4, 80.6, 60.5, 59.4, 51.3, 16.6, 16.2. HRMS calcd for C23H22NaO2 [M+Na]
+ 
353.1512; found 353.1522. 
2.3.3 Experimental procedure for Myoglobin-CO assay 
 
Figure 2.4 CO myoglobin assay. 
Orange curve: absorbance for deoxy-Mb. Blue curve: deoxy-Mb co-treated with BW-OTCO-
102/103 and NaClO. 
 
Our previously reported myoglobin-CO assay (two-compartment assay) was employed to 
confirm CO release from BW-OTCO-102/103.41  Specifically, a myoglobin solution in PBS (0.01 
M, pH = 7.4) (1.7 mg/mL, 2.9 mL) was degassed by bubbling with nitrogen for at least 20 min and 
a freshly prepared solution of sodium dithionite (17 mg/mL, 300 μL) was added to the myoglobin 
solution. Then the CO prodrug (3 mL, 1 mM) and NaClO (3 mL, 1 mM) were added to the inner 
vial. After incubation for 2 h at 37 oC, the solution was cooled in an ice bath for 10 min to increase 
the solubility of CO in water. Then the UV-vis absorption spectra was recorded. The maximal 
absorption peak of deoxy-Mb at 560 nm is converted to two maximal absorption peaks of Mb-CO 
at 540 and 578 nm, indicating the formation of CO bounded myoglobin when it is treated with 
BW-OTCO-102 (Figure 2.4a) while there is no change of the deoxy-Mb curve after adding BW-
OTCO-103 (Figure 2.4b). 
2.3.4 Experimental procedure for the study of sensitivity of BW-OTCO-102 to various ROS 
Various ROS solutions were prepared according to literature procedures.85  A solution of 
BW-OTCO-102 (400 µL, 1 mM in acetonitrile (ACN) was added to 20 mL of PBS (pH 7.4, 10 
mM). After stirring at room temperature for 5 min, the freshly prepared ROS stock solution was 
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added to make a final concentration of 500 µM (1 mM for H2O2, 60 µM for NaClO). Additional 
ACN was added to maintain its final solution of 10%.  The resulting mixture was incubated at 37 
°C for 30 min. CO release was monitored by the formation of BW-OTCP-102 using HPLC. The 
experiments were triplicated, and the results are reported as mean ± SD (n = 3). 
 
 
Figure 2.5 The sensitivity of BW-OTCO-102 to various ROS at 37 oC 
 
2.3.5 Experimental procedure for study of stability of BW-OTCO-101/102 in the absence of 
ROS 
A solution of BW-OTCO-101/102 (800 µL, 500 µM in ACN) was added to 20 mL of PBS 
(pH 7.4, 10 mM) in a vial. Additional ACN was added to maintain its final solution of 10%. The 
resulting solution was incubated at 37 °C for 48 h. The solution was then analyzed using HPLC. 
All the experiments were triplicated, and the results are reported as mean ± SD (n = 3).  As shown 
in Figure 2.6, both BW-OTCO-101 and BW-OTCO-102 are very stable even after 48 h’s 
incubation in the absence of ROS. 
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Figure 2.6 The stability of BW-OTCO-101 and BW-OTCO-102 in the absence of ROS. 
 
2.3.6 Experimental procedure for CO release kinetics of BW-OTCO-101/102 in response to 
hypochlorite 
A solution of BW-OTCO-101/102 (20 µM) and NaClO (40 or 60 µM) or KO2 (500 µM) 
or 1O2 (500 µM) in 10% of ACN in PBS (pH = 7.4) was sealed and incubated at 37 °C.  At each 
defined time point, 500 µL of the reaction mixture was taken out and added into a vial containing 
Na2SO3 (100 µL, 250 mM) to quench the reaction. The resulting solution was then analyzed by 
HPLC (column: Waters C18 3.5 μM, 4.6×100 mm, injection loop volume: 20μL). CO release was 
determined by monitoring the formation of the product and the consumption of the reaction 
intermediate as in the case of BW-OTCO-101 or prodrug (BW-OTCO-102). The mobile phase 
was acetonitrile ACN/H2O (containing 0.05% trifluoroacetic acid). Detailed conditions are 
summarized in Table 2.1. 
Table 2.1 The HPLC condition used for analysis 
  BW-OTCO-101 BW-OTCO-102 
Eluent 
conditions 
0~5 min, 60%~80% ACN; 5~10 
min, 80%~95% ACN; 10-13 min, 95%~ 
60% ACN. 
0~8 min, 30%~80% 
ACN; 8~15 min, 80%~95% 
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ACN; 15-18 min, 95%~ 30% 
ACN. 
tR 
(min)  
Prodrug: 10.9 ± 0.2;  
Intermediate: 4.2 ± 0.1; 4.9 ± 0.1; 
Product: 10.5 ± 0.1 
Prodrug: 13.8 ± 0.1;  
Product: 13.0 ± 0.1 
 
 
Figure 2.7 HPLC chromatogram of BW-OTCO-101 in the presence of 40 µM ClO- 
 
Figure 2.8 HPLC chromatogram of BW-OTCO-102 in the presence of 40 µM ClO- 
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Figure 2.9 HPLC chromatogram of BW-OTCO-102 in the presence of 500 µM O2
- 
 
 
Figure 2.10 HPLC chromatogram of BW-OTCO-102 in the presence of 500 µM 1O2 
 
2.3.7 Experimental procedure for synergetic effect study of CO prodrugs with Dox in killing 
cancer cells 
Hela cells and H9C2 cells were seeded in 96-well plates and cultured in DMEM 
supplemented with 10% FBS and 1% penicillin/streptomycin at 37 °C under 5% CO2 for 24 h. The 
cells were either incubated with doxorubicin (1% DMSO DMEM solution, 0 to 4 µM) or a mixture 
of doxorubicin and indicated compounds (1% DMSO DMEM solution, 0 to 4 µM for doxorubicin) 
for 24 h. After removal of the medium, the plate was washed with 150 µL/well of PBS and the cell 
was fixed with 4% paraformaldehyde for 1 h at room temperature. The solution in the well was 
then removed and 100 µL of 0.5% crystal violet staining solution was added to each well. After 
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incubation for 15 min at room temperature, the plate was washed with 200 µL of DI water for each 
well twice, followed by the addition of 100 µL/well of acetic acid solution (33%) to dissolve the 
dye. Absorbance at 615 nm was then measured by using a Perkin Elmer 1420 multi-label counter. 
Cell viability was measured, and the results were normalized to the vehicle group. The experiment 
was triplicated, and the results are expressed as mean ± SD (n = 3). The results have not shown 
significant difference. 
 
Figure 2.11 The lack of synergistic effects of control compounds with Dox 
 
 
Figure 2.12 The lack of synergistic effects of BW-OTCO-102 with Dox in H9C2 cells 
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2.3.8 Experimental procedure for cytotoxicity study of CO prodrugs and their respective 
products to H9C2 cells 
H9C2 cells were seeded in 96-well plates and cultured in Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 1% 
penicillin/streptomycin at 37 °C under 5% CO2 for 24 h. H9C2 cells were incubated in DMEM 
containing vehicle (1% DMSO) and doxorubicin or the indicated compounds for 24 hours. After 
removal of the medium, the plate was washed with 150 µL/well and the cell was fixed with 4% 
paraformaldehyde for 1 h at room temperature. The solution in the well was then removed and 100 
µL of 0.5% crystal violet staining solution was added to each well. After incubation for 15 min at 
room temperature, the plate was washed with 200 µL DI water for each well twice and added 100 
µL/well acetic acid solution (33%) to dissolve the dye. Absorbance at 615 nm was then measured 
by using a Perkin Elmer 1420 multi-label counter. Cell viability was measured and the results were 
normalized to the vehicle group. The experiments were triplicated and the results are expressed as 
mean ± SD (n = 3). The result has not shown significant difference. 
 
Figure 2.13 The cytotoxicity of BW-OTCO/OTCP-102 to H9C2 cells 
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2.4 Conclusion 
In conclusion, we have successfully developed a strategy for organic CO prodrugs, which 
can selectively release CO in response to both exogenous and endogenous ROS. Such CO prodrugs 
can selectively delivery CO to cells with elevated ROS levels (e.g. cancer cells and cells with 
activated inflammatory responses). Additionally, such CO prodrugs also sensitized cancer cells to 
Dox treatment, which could potentially reduce the dosage of Dox used, and thereby alleviate Dox-
related side effects. In summary, we strongly believe that the CO prodrugs described herein could 
serve as powerful tools for future studies of CO’s various therapeutic indications. 
2.5 Statements 
The much of the results in this chapter has been published in Org. Lett. (Pan, Z; Zhang, J; 
Ji, K; Chittavong, V; Ji, X; Wang, B. Organic CO Prodrugs Activated by Endogenous ROS. Org. 
Lett. 2018, 1, 8-11.). In this chapter, Wang, B conceived the initial idea, and supervised the study. 
I and Ji, X co-designed the CO prodrug and I perform the study.  Chittavong, V conducted studies 
of the reaction kinetics. Zhuang, J and Ji, K conducted the in vitro biology studies.  
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3 ESTERASE-SENSITIVE AND PH-CONTROLLED CARBON MONOXIDE 
PRODRUGS FOR TREATING SYSTEMIC INFLAMMATION 
3.1 Introduction 
As a well-recognized gasotransmitter, carbon monoxide imparts pleotropic pharmacologic 
effects, and most of the mechanistic underpinning is at least partially associated with its strong 
anti-inflammatory effect.86-90 For example, CO has been shown to confer beneficial effects in 
mouse models of inflammation bowel diseases,91 sepsis92 and ischemia reperfusion93, among 
others, partially by dampening the systemic inflammation. These results indicate CO as a very 
promising alternative to manage cytokine release syndrome (CRS), which can be caused by a wide 
range of pathological conditions including infections, organ injuries, lupus and rheumatoid 
arthritis, among others. It is also widely observed as an adverse effect for cancer 
immunotherapies.94 Under severe conditions (i.e. cytokine storms), CRS can lead to multiple organ 
dysfunction and even death.95 Current therapies in clinic largely rely on the administration of 
antibodies to neutralize cytokines, such as Tocilizumab.96 However, antibody therapy as such often 
compromises the immune response of the host, and thereby makes the host susceptible to 
infections, and also is not compatible with immunotherapies. Consequently, alternative therapies 
with new mechanisms of action are highly desirable. The strongly anti-inflammatory effect of CO 
puts it in a unique position for further examination and development for CRS. However, finding 
an optimal method for CO delivery for eventual clinical applications has been a tortuous path.  
Although inhaled CO has proven to be quite tolerable in humans at low dosage,97 and 
several clinic trials using inhaled CO are on-going, gaseous CO is not an ideal way of delivery for 
wide-spread application due to difficulties in dosage control and in addressing individual 
variability, among others.87 In order to mitigate these limitations, enormous efforts have been 
71 
devoted to the development of CO donors to trap CO in a pill, and some very exciting progresses 
have been achieved, including immobilized carbonyls using transition metals,68, 88, 98-108 commonly 
referred to as releasing molecules (CORMs), and photo-sensitive metal-free CORMs.34, 109  Our 
lab has been working on developing organic CO prodrugs with different triggers.42, 110-116 However, 
most of these CO prodrugs release CO either spontaneously upon dissolution or in response to a 
single stimulus, and very few is known to release CO with multiple triggers. In 2017, Schiller and 
co-workers developed the very first manganese-based CORMs controlled by an “OR” logic gate, 
which is sensitive to either visible light irradiation or ROS.117 Subsequently, the Berreau group 
also devised a metal-free CORMs gated by a “AND” logic triggers with visible light, thiol species 
and oxygen, affording more spatially specific CO release in cancerous cells.69 Evidently, these 
elegant CORMs showcased the advantages of CORMs with multiple triggers over the ones with 
just one single trigger, and could be potentially employed for targeted delivery. For in-vivo 
applications, we are interested in CO prodrugs, which would respond to multiple endogenous 
triggers. Herein, we describe our efforts toward CO prodrugs with two endogenous triggers. These 
CO prodrugs exhibit specific CO release in a dual-response fashion to esterase and physiologic pH 
environment. One representative CO prodrug showed intracellular CO release and recapitulated 
CO-associated anti-inflammatory effects in Raw264.7 cells. Furthermore, this CO prodrug 
conferred significant protective effects in a LPS-induced systemic inflammation mouse model. To 
the best of our knowledge, this is the very first example of organic CO prodrugs that release CO 
in response to multiple endogenous triggers.  
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3.2 Results and discussion 
3.2.1 Design of esterase-sensitive and pH-controlled CO prodrugs 
Figure 3.1 shows the design principle of such CO prodrugs. Unlike its structural analogue 
C, which is known to undergo facile cheletropic reaction to extrude CO at ambient temperature or 
lower, compound with scaffold A is highly thermally stable. We reasoned that decorating the 
bicycle ring with an electron donating (EDG) and a leaving group (LG) at C5 and 6 position 
respectively would make compound A a potential CO prodrug, provided that the EDG can be easily 
biotransformed into an electron withdrawing group (EWG) under physiological conditions. In the 
absence of endogenous stimuli, compound A is expected to be very stable in aqueous solution. 
However, in the presence of an endogenous stimulus, the EDG can be transformed into an EWG 
to yield compound B, which can undergo beta-elimination under physiologic pH to afford 
intermediate C for CO release. CO prodrugs as such are dual-responsive to two endogenous 
triggers in a sequential manner and may yield more spatially specific CO release profiles as 
compared to others with no or a single trigger. Another practical advantage of such a design is 
sample stability during preparation of the prodrug solution for administration and stability in the 
stomach if administered orally. 
 
Figure 3.1 The schematic illustration of the CO prodrugs with two triggers. 
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3.2.2 Synthesis of esterase-sensitive and pH-controlled CO prodrugs 
To establish the proof of concept, we designed and synthesized several CO prodrugs 6a-d 
with the EDG and the leaving group being an acetal and sulfonyl group, respectively (Scheme 1). 
CO prodrugs as such are expected to be dual-responsive to esterase and physiologic pH 
environment. As shown in Scheme 1, compound 1118 was reduced to alcohol compound 2, which 
was further oxidized to aldehyde 3. The Diels-Alder cycloaddition between compound 3 and 4 
went smoothly in refluxing toluene to yield compound 5, which was readily transformed into the 
CO prodrugs 6a-d in the presence of RuCl3. 
 
Scheme 3.1 The synthesis of CO prodrugs.  
Reagents and conditions: i) DIBAL, CH2Cl2, -78 
oC-r.t., 70%; ii) DMP, CH2Cl2, 0 
oC, 
74%; iii) toluene, reflux, 65%; iv) (RCO)2O, RuCl3, r.t. 50-70%. 
 
3.2.3 CO release kinetics study 
With these compounds in hand, we tested their CO release profiles in response to an 
esterase and physiologic pH. Initially, we confirmed that compound 5 release CO in phosphate 
buffer saline (PBS) buffer (pH = 7) with a half-life of about 30 min and the CO release was 
validated by a CO-myoglobin assay and fully elucidating the structure of the inactive product 7 
after CO release (Figure 3.2). As expected, compound 6a-c released CO in the presence of porcine 
liver esterase (PLE) in PBS buffer with release half-life ranging from 30 min to 8 h. The acetal 
group in 6a is so sensitive to the PLE that the prodrug is totally consumed within 2 mins with the 
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formation of compound 5, which underwent beta-elimination to afford compound 7. With the 
increasing steric bulk of the R group, the rate of esterase-mediated hydrolysis showed a 
significance decrease, eventually becoming the rate-limiting step with no build-up of compound 5 
throughout the experiment. Especially for 6d, no hydrolysis product was observed in the presence 
of PLE even after 36 h of incubation. Having confirmed that PLE mediated CO release from 6a-
c, compound 6a was selected to confirm the specificity of CO release in response to PLE and 
physiologic pH. The results showed that no hydrolysis (formation of 5) was observed in the 
absence of PLE even after 6 h of incubation either in PBS buffer (pH = 7) or simulated gastric 
fluid (SGF, pH = ~1). Meanwhile, incubation of 6a in the SGF containing PLE led to the formation 
of 5 within 2 mins. However, no beta-elimination (formation of 7) was observed even after 7 h of 
incubation at 37 oC. Collectively, these results unambiguously indicated that the CO release from 
compound 6a is gated by both PLE and physiologic pH environment. 
 
Figure 3.2  Release kinetics of CO from prodrugs 6a-c in the presence of PLE (3 U/mL) 
in 5% of DMSO in PBS at 37 oC. 
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To further validate CO release from 6a in response to esterase and physiologic pH, we 
tested the CO release profile of 6a in mouse, rat, rabbit and human serum by using HPLC. 
Interestingly, the results showed that the esterase mediated hydrolysis of 6a (formation of 5) in 
rabbit, rat and mouse serum is very fast as expected with half-lives of around 30 mins, 10 mins 
and 3 mins respectively. However, the hydrolysis of 6a is quite sluggish in human serum with a 
half-life of around 14 h. Moreover, the beta-elimination step of intermediate 5 is unexpectedly 
slow and is not finished even after 20 h in all the sera tested, as compared to only 3 h in PBS. This 
is presumably attributed to the binding of 5 to some serum proteins, which may hinder the beta-
elimination. Special attention should be paid to the release kinetics difference among different 
species. Such information will be especially useful and important in guiding future optimization 
work.  
 
3.2.4 Cell imaging study 
Due to the fast release kinetics of 6a in response to PLE and physiologic pH, it was selected 
for further validation in a biologic milieu. Initially, the intracellular CO release of 6a was studied 
in Raw264.7 cells using a reported CO fluorescent probe COP-1. As shown in Figure 3.3, the cells 
treated with COP-1 and 6a showed much enhanced green fluorescence as compared to the one 
treated with COP-1 only, indicating intracellular CO release from 6a. No decrease in cell viability 
was observed throughout the experiment according to a WST-8 cell proliferation assay, and 
compound 7 did not show any cytotoxicity even at concentration up to 200 M.  
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Figure 3.3 Cell imaging studies of CO release from 6a  
Cells treated with COP-1 (1 M) only (a-b) or COP-1 and 6a (50 M) (c-d). Scale bar: 20 
m. 
 
3.2.5 Anti-inflammatory study of CO prodrugs 
 
Figure 3.4 The anti-inflammatory effects of 6a in LPS-challenged Raw264.7 cells. 
The mean of each concentration of 6a and 7 treated group was compared with LPS-only 
group by two-sample t-test. *: p<0.05; **: p<0.01. 
 
As shown in Figure 3.4, compound 6a exhibited dose-dependent inhibition of LPS induced 
TNF- secretion, while no such effects were obtained with the inactive control compound 7, 
suggesting that the observed anti-inflammatory effects were attributed to the CO release from 6a. 
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It is worth pointing out that the concentration needed to produce the anti-inflammatory effect is 25 
M, which seems to be less potent as compared to other CORMs. The underlying reasons are two-
fold: Only one equivalent of CO is released from 6a as compared to two or more equivalents of 
CO released from metal-based CORMs; the release half-life of CO prodrug also determines the 
real effective CO concentrations. High concentrations of CO prodrugs with slow release rate does 
not necessarily mean high concentration of CO. 
 
Figure 3.5 The protective effects of prodrug 6a against LPS-induced liver injuries 
The effects were indicated by the suppression of TNF- (A), ALT(B) and AST levels 
(C). D-E) H&E staining of liver tissue in the vehicle control (D), LPS (E), and 6a (10mg/kg) 
treatment group (F). **: p<0.01. 
 
Having confirmed that compound 6a is able to release CO in response to intracellular 
esterase and physiologic pH to recapitulate CO-associated anti-inflammatory effects, we next 
evaluated its anti-inflammatory and liver protective effects in a LPS induced systemic 
inflammation mouse model.119 C57 mice were pre-treated with 6a, 7 or the vehicle 30 min before 
LPS injection (i.p. 10 mg/kg). After 6 h, mice were sacrificed, and blood and liver were harvested 
for biomarker analysis including TNF-, ALT and AST, and H&E staining, respectively. As shown 
in Figure 5A, treatment with 6a dose-dependently dampened the LPS-induced systemic 
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inflammation as indicated by significant decreases in the serum TNF- level. In addition, 6a also 
dose-dependently alleviated LPS-induced liver injury as evidenced by the decrease in the ALT and 
AST levels (Figure 5B, C). The liver H&E staining results further confirmed the protective effects 
of 6a (Figure 5F) against LPS-induced acute liver injury (Figure 5E). Meanwhile, no such effects 
were observed with the inactive control compound 7. Collectively, these results firmly established 
compound 6a as a promising CO prodrug for the treatment of sepsis or other inflammation related 
organ injuries. 
3.3 Experimental Section 
3.3.1 General information 
All reagents and solvents were of reagent grade and were purchased from Aldrich. Column 
chromatography was carried out using flash silica gel (Sorbent 230–400 mesh) and P-2 Gel (Bio-
Gel, particle size range 45- 90 μm). TLC analyses were conducted on silica gel plates (Sorbent 
Silica G UV254). 1H-NMR (400 MHz) and 13C-NMR (100 MHz) spectra were recorded on a 
Bruker Avance 400 MHz NMR spectrometer.  Mass spectral analyses were performed on a Q-
TOF micro (Waters Micromass) by the GSU Mass Spectrometry Facilities. Please refer to SI for 
the synthesis of compound 2 and 3. The purity of all the tested compounds is over 95% as 
determined by HPLC. 
A mouse macrophage cell line, RAW 264.7 (ATCC® TIB-71™), was used for the in vitro 
studies. RAW 264.7 cells were maintained in DMEM (Dulbecco’s Modified Eagle’s Medium) 
supplemented with 10% fetal bovine serum (MidSci; S01520HI) and 1% penicillin-streptomycin 
(Sigma-Aldrich; P4333) at 37 °C with 5% CO2. The media was changed every other day. All the 
experiments were done within 10 passages of RAW 264.7 cells. All the tested compounds were 
dissolved in 100% DMSO to yield the respective stock solution.  
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Lipopolysaccharide (LPS) was purchased from Sigma Chemical Co.. Mouse TNF-α ELISA 
kits were purchased from eBiosscience. Distilled water was filtered through a Milli-Q system from 
EMD Millipore Corporation. LPS was dissolved in saline (1mg/mL) before injection. C57BL/6 
mice were purchased from Sichuan Dashuo Animal Company. The mice were maintained under 
controlled temperature and humidity with certified standard diet and water adlibitum and 
habituated to animal facilities for 1 week before the experiment. The experimental protocols were 
approved by Animal Use and Care Committee of Sichuan University (Approval No. 2018117A) 
and followed the guidelines of the Care and Use of Laboratory Animals of China Association for 
Laboratory Animal Science. 
3.3.2 Experimental procedure for the synthesis of Esterase-sensitive and pH-controlled CO 
prodrugs 
Synthesis of (1S,4S)-1,4-dimethyl-7-oxo-5,6-diphenyl-3-
(phenylsulfonyl)bicyclo[2.2.1]hept-5-ene-2-carbaldehyde (5): To a solution of 4 (0.8 mmol, 208 
mg) in toluene (10 mL), was added compound 3 (0.9 mmol, 177 mg).  The mixture was heated 
under reflux for 5 h. Then, the reaction mixture was concentrated under vacuum, and the obtained 
residue was directly purified on a silica gel column (hexane: EtOAc = 5:1) to afford the desired 
product as a white solid (270 mg, yield: 60% over two steps). 1H NMR (CDCl3): δ 10.13 (d, J = 
5.3 Hz, 1H), 7.77 – 7.71 (m, 2H), 7.67 (d, J = 7.5 Hz, 1H), 7.54 (t, J = 7.8 Hz, 2H), 7.37-7.41 (m, 
2H), 7.31 – 7.20 (m, 6H), 7.10 – 7.03 (m, 2H), 4.17 (d, J = 10.3 Hz, 1H), 3.04 (dd, J = 10.3, 5.3 
Hz, 1H), 1.44 (s, 3H), 1.35 (s, 3H) ppm. 13C NMR (CDCl3): δ 198.9, 196.2, 157.5, 141.9, 140.2, 
139.7, 139.6, 134.5, 133.8, 133.5, 130.7, 129.8, 129.5, 128.5, 128.2, 127.9, 127.7, 70.9, 59.0, 57.6, 
57.1, 12.4, 11.3 ppm. HRMS calcd for C28H24O4SNa [M+Na]+: 479.1293; found: 479.1283.  
General procedure for the synthesis of 6a-d 
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To a solution of 5 (0.1 mmol, 45 mg) in the corresponding anhydride (0.1 mL) was added 
RuCl3 (0.01 mmol, 2 mg）in one portion, and the mixture was stirred at room temperature for 12 
h. The reaction was then quenched with water (10 mL) and extracted with ethyl acetate (3 × 20 
mL). The combined organic layer was dried over anhydrous Na2SO4 and concentrated under 
reduced pressure. The obtained residue was purified on a silica gel column to afford the title 
compound. 
((1S,4S)-1,4-dimethyl-7-oxo-5,6-diphenyl-3-(phenylsulfonyl)bicyclo[2.2.1]hept-5-en-2-
yl)methylene diacetate (6a) 
  The title compound was synthesized according to the general procedure with compound 
5 (0.1 mmol, 45mg) and acetic anhydride (0.1 mL). 1H NMR (CDCl3): δ 7.77 (d, J = 2.7 Hz, 1H), 
7.63 (d, J = 8.4 Hz, 2H), 7.47 (t, J = 7.9 Hz, 2H), 7.34 – 7.28 (m, 7H), 7.23 – 7.17 (m, 3H), 4.12 
(d, J = 11.0 Hz, 1H), 3.24 (dd, J = 11.0, 2.7 Hz, 1H), 2.13 (s, 3H), 2.05 (s, 3H), 1.47 (s, 3H), 1.02 
(s, 3H) ppm. 13C NMR (CDCl3): δ 196.4, 168.8, 168.6, 142.9, 141.3, 138.7, 134.7, 134.0, 134.0, 
130.7, 129.3, 128.4, 127.7, 127.7, 127.5, 127.3, 88.8, 69.8, 56.8, 55.9, 50.7, 20.9, 20.9, 13.3, 13.0 
ppm. HRMS calcd for C32H30O7SNa [M+Na]+: 581.1610; found: 581.1635. 
((1S,4S)-1,4-dimethyl-7-oxo-5,6-diphenyl-3-(phenylsulfonyl)bicyclo[2.2.1]hept-5-en-2-
yl)methylene dibutyrate (6b) 
  The title compound was synthesized according to the general procedure with compound 
5 (0.1 mmol, 45mg) and butyric anhydride (0.1 mL). 1H NMR (CDCl3): δ 7.70 (d, J = 7.7 Hz, 2H), 
7.63 (t, J = 7.5 Hz, 1H), 7.47 (t, J = 7.8 Hz, 2H), 7.28 – 7.17 (m, 8H), 7.16 – 7.07 (m, 2H), 6.66 
(s, 1H), 3.80 (d, J = 5.6 Hz, 1H), 3.14 (d, J = 5.1 Hz, 1H), 2.27 (t, J = 7.4 Hz, 2H), 2.19 (t, J = 7.4 
Hz, 2H), 1.58-1.66 (m, 4H), 1.32 (s, 3H), 1.26 (s, 3H), 0.92-1.97 (m, 6H) ppm. 13C NMR (CDCl3): 
δ 198.1, 171.7, 170.7, 142.8, 139.8, 139.4, 134.0, 133.9, 133.6, 130.6, 129.4, 129.3, 128.7, 128.2, 
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127.7, 127.6, 127.4, 88.0, 67.6, 56.2, 54.7, 47.1, 35.5, 35.5, 17.9, 17.8, 13.5, 13.4, 12.7, 10.2 ppm. 
HRMS calcd for C36H38O7SNa [M+Na]+: 637.2236; found: 637.2265. 
((1S,4S)-1,4-dimethyl-7-oxo-5,6-diphenyl-3-(phenylsulfonyl)bicyclo[2.2.1]hept-5-en-2-
yl)methylene dicyclopropanecarboxylate (6c)   
The title compound was synthesized according to the general procedure with compound 5 
(0.1 mmol, 45mg) and cyclopropanecarboxylic anhydride (0.1 mL). 1H NMR (CDCl3): δ 7.72 (d, 
J = 2.6 Hz, 1H), 7.67 – 7.63 (m, 2H), 7.60 (t, J = 7.5 Hz, 1H), 7.46 (t, J = 7.8 Hz, 2H), 7.40 – 7.31 
(m, 4H), 7.25-7.29 (m, 3H), 7.18-7.22 (m, 3H), 4.12 (d, J = 11.0 Hz, 1H), 3.23 (dd, J = 11.0, 2.6 
Hz, 1H), 1.68 – 1.60 (m, 1H), 1.53 (s, 3H), 1.36-1.42 (m, 1H), 1.12 – 1.03 (m, 5H), 1.04 – 0.77 
(m, 6H) ppm. 13C NMR (CDCl3): δ 196.8, 172.6, 172.5, 143.0, 141.4, 138.8, 134.7, 134.2, 133.9, 
130.9, 130.8, 129.2, 128.3, 127.7, 127.6 127.4, 127.3, 88.8, 69.9, 57.0, 56.0, 50.8, 13.3, 13.0, 12.8, 
12.6, 9.4, 9.2, 9.1, 8.6 ppm. HRMS calcd for C36H34O7SNa [M+Na]+: 633.1923; found: 633.1951. 
((1S,4S)-1,4-dimethyl-7-oxo-5,6-diphenyl-3-(phenylsulfonyl)bicyclo[2.2.1]hept-5-en-2-
yl)methylene bis(2,2-dimethylpropanoate) (6d)   
The title compound was synthesized according to the general procedure with compound 5 
(0.1 mmol, 45mg) and pivalic anhydride (0.1 mL). 1H NMR (CDCl3): δ 7.78 (d, J = 7.5 Hz, 2H), 
7.67 (t, J = 7.5 Hz, 1H), 7.53 (t, J = 7.8 Hz, 2H), 7.24-7.28 (m, 5H), 7.18-7.23 (m, 3H), 7.11-7.16 
(m, 2H), 6.32 (s, 1H), 3.61 (d, J = 6.4 Hz, 1H), 2.98-3.04 (m, 1H), 1.44 (s, 3H), 1.30 (s, 3H), 1.18 
(s, 9H), 1.16 (s, 9H) ppm.  13C NMR (CDCl3): δ 198.2, 176.8, 175.4, 142.8, 138.9, 134.3, 133.9, 
133.6, 130.6, 129.5, 129.4, 128.7, 128.2, 127.7, 127.6, 127.4, 89.3, 67.7, 56.0, 54.5, 48.0, 39.0, 
38.6, 29.7, 27.0, 26.8, 12.6, 10.9 ppm. HRMS calcd for C36H34O7SNa [M+Na]+: 665.2549; found: 
665.2545. 
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3.3.3 Experimental procedure for cell imaging study 
RAW 264.7 cells were seeded on coverslips in 6-well plate at an initial density of 
10,000/well one day before the imaging experiment. Compounds were dissolved in DMSO as 
stock solution. Final concentration of 1 M of COP-1 and 50 M of 6a were added into the cell 
culture. All the final samples contained 1% DMSO. After adding the compound, the cells were 
incubated under 37 °C for 5 h. The cell samples were then fixed with 4% paraformaldehyde. The 
cells were then washed with PBS again twice and the coverslips with cells were immersed in DI 
water. The coverslips S19 were mounted onto glass slides using the mounting media without DAPI 
(ProLong® Live Antifade Reagent; P36974). The fluorescent imaging was performed under FITC 
channel (excitation: 490 nm, emission: 525 nm) using a Zeiss fluorescent microscope (Axio Vert. 
A1). 
 
3.3.4 Experimental procedure for anti-inflammatory effects study 
RAW 264.7 cells were seeded in 96-well plates at an initial density of 10,000/well one day 
before the experiment. LPS was used to initiate the inflammatory response in RAW 264.7 cells. 
RAW 264.7 cells were pre-treated with different concentrations of 6a, 7 or sodium 
benzenesulfinate for 4 h. All the final samples contained 1% DMSO. Thereafter, LPS was added 
into the cell culture media to make a final concentration of 1 g/mL. The cells were then incubated 
at 37 oC for another 1 h, and the cell culture supernatant was collected afterwards. Cell culture 
without LPS treatment was used as the control. The concentrations of TNF- in the cell culture 
supernatant were determined by a commercial ELISA kit (ELISA Ready-SET-Go!®-eBioscience). 
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3.3.5 Experimental procedure for the study of 6a’s Anti-inflammatory and liver protective 
effects in an LPS-simulated mouse model 
Six- to eight-week old male C57BL/6 mice weighting 22-25 g were randomly divided into 
five groups of eight individuals. Mice received single dose treatment of either 6a (i.p., 5, 10 and 
20 mg/kg) or the vehicle (solutol : saline = 1:9) 30 min before the injection of LPS (i.p., 10mg/kg). 
After 6 h, the mouse serum in each group was collected by cardiac puncture after anesthesia and 
was centrifuged at 3000 rpm for 10 min. The supernatant was then taken for the analysis of TNF-
 (Elisa), ALT and AST levels (biochemical automatic analyzer, SRL, Tokyo, Japan). After the 
blood sampling, the mice were sacrificed, and the liver was harvested, rinsed with saline and fixed 
with 10% formalin. The liver tissues were embedded with paraffin, sliced to 5 μm sections, and 
stained with hematoxylin-eosin (H&E). Mouse liver histopathology images were acquired using a 
microscope (Zeiss AX10 imager A2/AX10 cam HRC).  
3.4 Conclusion 
In this work, we describe efforts toward organic CO prodrugs with dual-responsive 
endogenous triggers. One representative CO prodrug showed significant anti-inflammatory effects 
both in vitro and in a LPS-simulated systemic inflammation model. These results firmly establish 
such CO prodrugs as either research tools or candidate compounds for the treatment of systemic 
inflammation or inflammation related organ injuries. 
3.5 Statements 
The much of the results in this chapter has been published in J. Med. Chem. (Ji, X; Pan, Z; 
Li, C; Kang, T; LK De la Cruz, L; Yang, L; Yuan, Z; Ke, B; Wang, B. Esterase-sensitive and pH-
controlled Carbon Monoxide Prodrugs for Treating Systemic Inflammation. J. Med. Chem. 2019, 
6, 3163–3168.). In this chapter, Wang, B conceived the initial idea, and supervised the study. I and 
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Ji, X co-designed the CO prodrug and perform the study.  LK De la Cruz, L and Yuan, Z conducted 
studies of the reaction kinetics and some of the synthesis. I and Ji, X conducted the in vitro biology 
studies. Li, C; Kang, T; and Yang, L conducted in vivo studies. Ke, B supervised and/or performed 
the in vivo studies, analyzed and interpreted the data. 
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Appendix B Spectra of compounds in the study of ROS-activated CO prodrugs 
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Appendix C Spectra of compounds in the study of esterase-sensitive and pH-
controlled CO prodrugs  
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